CURRICULUM VITAE for Dr. Fred WolfeCURRICULUM VITAE for Dr. Fred Wolfe

FREDERICK WOLFE, M.D.
1035 N. Emporia, Ste.230
Wichita, KS 67214
(316) 263-2125
FAX (316)-263-0761

Clinical Professor of Internal Medicine

EDUCATION

Queens College, New York B.A.1954-1958
State University of New York M.D. 1962-1966 Medicine

RESEARCH AND/OR PROFESSIONAL EXPERIENCE

2001 Master - American College of Rheumatology Award
1995-The 1995 Distinguished Rheumatologist Award - American College of Rheumatology
1992- Clinical Professor of Family & Community Medicine, University of Kansas School of Medicine.
1989- Clinical Professor of Medicine, University of Kansas School of Medicine.
1984- Adjunct Professor of Nursing, Wichita State University.
1983- Co-Director, Arthritis & Rheumatic Disease Unit, St. Francis Regional Medical Center.
1980-89 Clinical Associate Professor of Medicine, University of Kansas School of Medicine.
1979-80 Clinical Assistant Professor of Medicine, University of Kansas School of Medicine.
1978- Co-Director American Rheumatism Association Medical Information System.
1975-76 Director, Rheumatology Unit Wesley Medical Center, Wichita, Kansas.
1975-78 Director, Veteran's Administration Hospital Rheumatology Clinic, Wichita, Kansas.
1974- Director, Wichita Arthritis Center, Wichita, Kansas.
1971-73 Director, Internal Medicine Education, St. Joseph Hospital and Rehabilitation Center
1970-71 Resident, Medicine, University of Kansas Medical Center.
1968-70 Captain USAF MC Internal Medicine Section
1967-68 Resident, Medicine, State University, Kings County Medical Center, New York.
1966-67 Intern (straight medicine), State University, Kings County Medical Center, New York.

MEMBERSHIP IN PROFESSIONAL & SCIENTIFIC SOCIETIES

Diplomat, National Board of Medical Examiners, 1967
Diplomat, American Board of Internal Medicine, 1971
American College of Physicians, 1971
American Rheumatism Association, 1972-87
American College of Rheumatology, Fellow, 1987
     ACR Computer Committee, 1977
     ACR Uniform Database Committee, 1977
     ACR Glossary Subcommittee, 1979
     ACR Non-articular Rheumatism Study Group
       Secretary, 1977 - 1981
       Chairman, 1982 - 1983
     ACR Program Committee, 1985, 1987
     ACR Program Committee, Chairman N.A.R. Abstract section, 1990.
     ACR Subcommittee on functional status & disease severity in Rheumatoid Arthritis
     ACR Subcommittee on Clinical Trials
     ACR Health Care Research Committee
Central Region ACR-Program Committee, 1986-88
Central Region ACR-2nd V.P., 1988-1989
Central Region ACR-President-Elect and Program Chairman, 1990-1991
Central Region ACR-President, 1991-1992
Chairman, Fibrositis Criteria Committee, 1986
Kansas Chapter-Arthritis Foundation
     Executive Committee 1974-1976, 1984.
     Board of Directors 1974-1994
     Chairman, Professional Education Committee 1974-1991
     Chairman, Medical and Scientific committee-various years 1974-1982.
American Pain Society, 1988-
     Membership Committee 1996-1998
Institute of Objective Measurement, Board of Directors, 2003
International Society for the Study of Pain, 1988-
     Chairman, Fibromyalgia special interest group.
American Association for the Advancement of Science, 1987-
Osteoarthritis Research Society, 1993-
British Society for Rheumatology, 1997

SELECTED ACADEMIC Visiting Professorships - Invited lecturships

International
ARC Epidemiology Research Unit, Manchester, U.K.
Fundacion Rheumatologica Argentina
University Hospital Maastricht, Netherlands
Belgian Pain Society, Brussels, Belgium
University of Leuven, Belgium
Heinola Rheumatism Hospital, Heinola, Finland
Royal College of Medicine, Edinburgh
Ben-Gurion University, Beer-Sheva, Israel
Royal Society for Medicine, London, England
King's College Hospital, London, England
University of Glasgow, Scotland
University of Manchester, Manchester, England
University of Leeds, Leeds, England
Combined Hospitals, Bath, England
Canadian Rheumatism Association, Lake Louise, Canada
Zürich University, Switzerland
University of Leiden, The Netherlands
International League Against Rheumatism, Brazil
OMERACT, Cairns, Australia
Swiss Rheumatologic and German Rheumatologic Society, Bad Sackingen, Germany
European League Against Rheumatism, Athens, Greece
Fibromyalgia Symposium, Tranos, Sweden
International League Against Rheumatism, Barcelona, Spain
National Insurance Conference on Fibromyalgia. Oslo, Norway
University of Lübeck-Bad Bramstedt, Germany
Scandinavian Rheumatology Association, Lillihammer, Norway
Australian Rheumatism Association, Melbourne Australia
European Research Society, Ghent, Belgium
2nd International Conference on Myofascial Pain and Fibromyalgia. Copenhagen, Denmark
International Association for the Study of Pain, Adelaide, Australia

North America
Institute of Medicine, National Academy of Science
University of New York at Stony Brook, Stony Brook, N.Y.
Hospital for Special Surgery, New York City
Boston University, Boston, MA
University of Toronto, Toronto, Canada
Hospital for Joint Diseases, New York University Medical Center, N.Y
Creighton University, Omaha, Nebraska
University of California at San Francisco
University of Texas Health Science Centers, San Antonio, TX
National Institutes of Health, Bethesda, Maryland
University of Maryland, Baltimore, MD
John Hopkins University, Baltimore, MD
Southwest Medical School, Dallas, TX
Pfizer visiting Professorship – University of Oregon Health Sciences Center
University of Miami, Miami, FL
Physical Medicine Society, Vancouver, B.C., Canada.
ARAMIS, Stanford University, Stanford, CA
Walter Reed Medical Center, Washington, DC
American College of Rheumatology, Atlanta, GA
Arthritis Health Professions Association, Atlanta, GA
American Pain Society
Cleveland Clinic, Cleveland, OH
Vanderbilt University, Nashville, TN
University of Iowa, Des Moines, IA
Eastern Maine Medical Center, Portland
University of Oregon Health Sciences Center, Portland, OR
University of Saskatchewan, Saskatoon, SK
University of Calgary, Calgary, AL.
University of Missouri at Kansas City, Kansas City, MO
VA Medical Center, Leavenworth, KS
American College of Physicians Annual Meeting, Chicago, IL
University of Minnesota, Minneapolis, MN.
University of Tennessee, Knoxville, TN
St. Louis Rheumatism Society. St. Louis, MO.
Case Western Reserve University, Cleveland OH
University of Cincinnati, Cincinnati, OH
University of Wisconsin, Madison, Wisconsin
Brown University, Providence, RI
University of Missouri, Columbia, MO
State University of New York, Downstate Medical Center, NY

REFEREE - REVIEWER
American Family Physician
American Journal of Medicine
Annals of Internal Medicine
Annals of the Rheumatic Diseases
Arthritis and Rheumatism
Arthritis Care and Research
British Journal of Rheumatology
Clinical and Experimental Rheumatology
Clinical Rheumatology in practice
Clinical Rheumatology
Diabetic Medicine
Journal of Musculoskeletal Pain
Journal of Rheumatology
Journal of the American Medical Association
Journal of Clinical Epidemiology
Journal of Psychosomatic Research
New England Journal of Medicine
Pain
Osteoarthritis and Cartilage
Psychosomatic Medicine
Scandinavian Journal of Rheumatology
Seminars in Arthritis and Rheumatism
The Lancet
Western Journal of Medicine
Journal of Outcome Measurement

EXTERNAL REVIEWER
Arthritis Society of Canada
National Institutes of Health
National Dental Institute
Medical Research Council (Canada)
University of Toronto

EDITORIAL
Editorial Board, Arthritis Care and Research, 2003
Editorial Board, Arthritis and Rheumatism, 1994-1999
Editorial Board, Canadian Journal of Pain, 1994
Editorial Board. Clinical and Experimental Rheumatology, 1998
Editorial Board, Journal of Applied Measurement, 2000
Editorial Board, Journal Club Rheumatology - 1988
Editorial Board, Journal of Clinical Rheumatology, 1995
Editorial Board, Journal of Musculoskeletal Pain - 1992
Editorial Board, Journal of Rheumatology - 1991
Editorial Board, Rheumatology 1992
Consulting Editor, Arthritis Care and Research - 1987-1990
Associate Editor, Pain Management - 1990
 

PUBLICATIONS-ABSTRACTSPUBLICATIONS-ABSTRACTS

  1. Wolfe F: A Patient Determined History in the Rheumatic Diseases (abstract) American College of Physicians, Topeka, Kansas, 1976.
  2. >Diamond HS, Bankhurst AD, Willkens RF, Godfrey RG, Katz WA, Oliver JA, Shenker BM, Wolfe F: A Multicenter Double-Blind Comparison of Sulindac and Phenylbutazone in the Treatment of Acute Gout. XIV International Congress of Rheumatology, 1977.
  3. A Computer Version of the Uniform Database for Rheumatic Disease (UDRD) (Abstract). XIV International Congress of Rheumatology, 1977.
  4. Rowe HJ, Sigler JW, Wolfe F, April PA, Rosenberg AL, Schultz RT, Liang GC, Fowler FJ, Serbin RA: Comparison of Pirprofen and Aspirin in Rheumatoid Arthritis: A Multicenter Study (Abstract), XIV International Congress of Rheumatology, 1977.
  5. Wolfe F, Godfrey R: The Kansas Arthritis Centers Project (Abstract) American College of Physicians, Topeka, Kansas, 1978.
  6. Alexander S, Holmes C, Wolfe F: Lower Extremity Functional Testing (Abstract) ACR Meeting, Denver, 1979.
  7. Holmes C, Alexander S, Medina P, Wolfe F: A Functional Disability Index (Abstract), ACR Meeting, Denver, 1979.
  8. Medina P, Wolfe F, Alexander S, Holmes C: A Functional Database for Rheumatic Diseases (Abstract) ACR Meeting, Denver, 1979.
  9. Wolfe F: Computer Research in Clinical Practice (Abstract). Arthritis Rheum 25 (supp): S26-1982.
  10. Wolfe F: Nonarticular Symptoms in Fibrositis, Rheumatoid Arthritis, Osteoarthritis and Arthralgia Syndromes (Abstract). Arthritis Rheum 25 (supp): S146, 1982.
  11. Wolfe F, Kleinheksel SM: Functional Class, Vocational Ability and Measurements of Function (Abstract). Arthritis Rheum 25 (supp): S152, 1982.
  12. Wolfe F: Effect of Age Disease Duration and Disease Activity on Disability in Rheumatoid Arthritis (Abstract). Arthritis Rheum 26 (supp): S55, 1983.
  13. Wolfe F, Kleinheksel SM, Spitz P, Fries JF, Mitchell DM, Roth SH, Lubeck DF, Young DY: A Multi-Center Study of Hospitalization in Rheumatoid Arthritis (Abstract) Arthritis Rheum 26 (supp): S29, 1983.
  14. Wolfe F, Williams B, Medina P, Stone G: The Erythrocyte Sedimentation Rate (ESR) in Non-Inflammatory Rheumatic Disorders (Abstract). Arthritis Rheum 26 (supp): S48, 1983.
  15. Hawley DJ, Wolfe F: Remission in Rheumatoid Arthritis (Abstract). Arthritis Rheum 26 (supp): S26, 1983.
  16. Lane NE, Lubeck DP, Wolfe F, Mitchell D, Roth S, Fries JF: Post-Marketing Surveillance (PMS) of Anti-Rheumatic Drugs. (Abstract) Arthritis Rheum 27: (supp) S38, 1984.
  17. Caro XJ, Wolfe F, Johnston WH, Smith AL: A Controlled and Blinded Study of Immunoreactant Deposition at the Dermal-Epidermal Junction in Patients with Primary Fibrositis Syndrome. (Abstract) Arthritis Rheum 27:S76, 1984.
  18. Fries JF, Sharp J, Bloch DA, McShane DJ, Bluhm G, Forrester D, Cofton P, Weissman C, Genant H, Richman S, Wolfe F, Spitz P: Assessment of Radiologic Progression in Rheumatoid Arthritis (RA) A Randomized Controlled Trial. (Abstract) Arthritis Rheum 28:S69, 1985.
  19. Wolfe F, Cathey M, Kleinheksel S: Measurement of Gold Effectiveness: A Prospective Study. (Abstract) Arthritis Rheum 28:S89, 1985.
  20. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell D, Roth SH: A Multi-Center Study of Utilization and Costs in Rheumatoid Arthritis. (Abstract) Arthritis Rheum 28:S138, 1985.
  21. Hawley DJ, Wolfe F, Cathey MA: Serial Psychological Measurements in Rheumatoid Arthritis. (Abstract) Arthritis Rheum 28:S151, 1985.
  22. Altman, RD, Asch ES, Bloch D, Bole GG, Borenstein D, Brandt KD, Cooke DV, Christy W, Greenwald R, Hochberg M, Howell D, Kaplan, D, Koopman W, Longley S, McShane DJ, Mankin H, Medgser T, Meenan R, Mikkelsen W, Moskowitz R, Murphy W, Rothschild B, Sokoloff L, Wolfe F: Report of the osteoarthritis (OA) criteria subcommittee on classification of OA of the knee. (Abstract) Arthritis Rheum 29:S16, 1986.
  23. Wolfe F, Cathey MA, Hawley DJ, Schindler J: Recombinant gamma interferon in rheumatoid arthritis. (Abstract) Arthritis Rheum 29:S18, 1986.
  24. Pincus T, Callahan LF, Vaughn WK, Bradley L, Wolfe F: Minnesota Multiphaasic Personality Inventory (MMPI) scores indicate the presence of disease and not psychological abnormalities in rheumatoid arthritis (Abstract) Arthritis Rheum 29:S23, 1986.
  25. Wolfe F, Kleinheksel SM, Spitz P, Fries JF, Mitchell DM, Roth SH: Hospitalization for rheumatoid arthritis: effect of health policy changes.(Abstract) Arthritis Rheum 29:S23, 1986.
  26. Fries JF, Altman RD, Bloch DA, Carstens J, Cooke TD, Genant H, Gofton P, Groth H, McShane D, Murphy W, Sharp J, Spitz P, Wolfe F: Radiologic assessment of disease progression in osteoarthritis. (Abstract) Arthritis Rheum 29:S61, 1986.
  27. Sherrer YS, Young DY, Fries JF, Wolfe F, Mitchell DM: Comparability of Prediction of Rheumatoid Disability Outcome Across Populations. (Abstract) J Rheumatol 14:1987.
  28. Cathey MA, Wolfe F, Kleinheksel SM, Hawley DJ: The socio-economic impact of fibrositis.(Abstract) Arthritis Rheum 29:S63, 1986.
  29. Wolfe F, Khan MA: Familial rheumatoid arthritis: Epidemiological and clinical features (Abstract). Arthritis Rheum 30:11C, 1987.
  30. Cathey MA, Hawley D, Kleinheksel S, Wolfe F: Pain in Fibrositis: Lack of association with diagnostic criteria. (Abstract) Arthritis Rheum 30:10C, 1987.
  31. Hawley D, Cathey MA, Kleinheksel S, Wolfe F: A study of fibrositis symptoms over ten months. (Abstract) Arthritis Rheum 30:9C, 1987.
  32. Khan MA, Wolfe F, Kleinheksel SM, Khan MK: Clinical epidemiological and immunogenetic studies of familial and nonfamilial rheumatoid arthritis. (Abstract) Br J of Rheum 26:S1, p. 43, 1987.
  33. Wolfe F, Spitz P, Fries J: The clinical value of the HAQ disability index in patients with rheumatoid arthritis. (Abstract) Arthritis Rheum 30:S18, 1987.
  34. Cannon GW, Schindler JD, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway A, Jaffer AM, Weaver AL, Cogen L: Double-blind trial of recombinant interferon-gamma versus placebo in rheumatoid arthritis. (Abstract) Arthritis Rheum 30:S19, 1987.
  35. 35 Caro XJ, Kinstad NA, Russell IJ, Wolfe F: Increased sensitivity to health related questions in patients with primary fibrositis syndrome. (Abstract) Arthritis Rheum 30:B41, 1987.
  36. Wolfe F, Hawley DJ: Anxiety and depression in rheumatoid arthritis: A 4 year study of 400 RA patients (Abstract) Arthritis Rheum 30:S197, 1987.
  37. Wolfe F, Hawley DJ: Progression of depression in rheumatoid arthritis. (Abstract) Arthritis Rheum 30:S197, 1987.
  38. Hawley DJ, Cathey MA, Wolfe F: A study of fibrositis symptoms over twelve months (Abstract) Arthritis Rheum 30:S197, 1987.
  39. Cathey MA, Hawley DJ, Kleinheksel SM, Wolfe F: Pain in fibrositis: Lack of association with diagnostic criteria. (Abstract) Arthritis Rheum 30:S203, 1987.
  40. Wolfe F, Kleinheksel SM, Khan MA: Familial rheumatoid arthritis: Epidemiological and clinical features Arthritis Rheum 30:(suppl 1) S18, 1987. Also PANLAR 1986 Meeting Abstract Book, pp 161(Abstract B60).
  41. Khan MA, Wolfe F, Kleinheksel SM, Khan MK: Immunogenetic and epidemiological studies in non-familial and familial rheumatoid arthritis Federation Proceedings 46 (No:3):426, 1987.
  42. Khan MA, Wolfe F, Kleinheksel SM, Khan MK: Clinical, epidemiological and immunogenetic studies of familial and non-familial rheumatoid arthritis. Br J Rheumatol 26(Suppl.No:1):43, 1987.
  43. Yamashita TS, Khan MA, Wolfe E, Stastny P: Genetic epidemiology of familial rheumatoid arthritis (RA): Study of 70 multi-case families. Am J Hum Genet Abstract Book, pp. 1987.
  44. Khan MA, Yamashita TS, Stastny P, Wolfe F, Kleinheksel S, Khan MK: Familial rheumatoid arthritis and homozygosity for HLA-DR4. Arthritis Rheum 31:R29, 1988.
  45. Khan MA, Yamashita TS, Wolfe F, Kleinheksel S, Khan MK: Effect of gender and HLA-DR4 genotype in familial rheumatoid arthritis. Arthritis Rheum 31:R31, 1988.
  46. Khan MA, Yamashita TS, Wolfe F, Kleinheksel, Stastny P, Reynolds TL: Familial rheumatoid arthritis: Genetic epidemiology of 75 white multi-case families. In Immunobiology of HLA, Springer-Verlag, Berlin, Heidelberg (in press).
  47. Kleinheksel SM, Miller S, Pitteti KH, Cathey MA, Wolfe F: Evaluation of functional ability in rheumatic disorders by computerized assessment of simulated work (CASW). Arthritis Rheum 31(Suppl 4):S157, 1988.
  48. Cathey MA, Kleinheksel SM, Miller S, Pitetti, Wolfe F: Assessment of functional ability in patients with fibromyalgia. Arthritis Rheum 31(Suppl 4):S99, 1988.
  49. Wolfe F, Hawley DJ, Allen ML, Cathey MA, Kleinheksel SM: The age of death of parents of patients with rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Rheum 31(Suppl 4):S57, 1988.
  50. Cannon GW, Schindler JD, Emkey RD, Denes A, Cohen SA, Wolfe F, Weaver AL, Cogen L: Long term follow-up of recombinant interferon-gamma in rheumatoid arthritis. Arthritis Rheum 31(Suppl 4):S53, 1988.
  51. Cannon GW, Schindler JD, Kennedy SM, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L: Prospective two year follow-up of recombinant interferon-gamma in rheumatoid arthritis. Arthritis Rheum 32(Suppl4):D21, 1989.
  52. Wolfe F, Smythe HA, Yunus, MB, Bennett RM, Bombardier C, Goldenberg DM, Tugwell P, Multicenter Fibromyalgia Criteria Committee: Criteria for fibromyalgia. Arthritis Rheum 32(Suppl 4):S39, 1989.
  53. Wolfe F, Hawley DJ, Cathey MA: The risk of functional disability and its rate of development in patients with rheumatoid arthritis. Arthritis Rheum 32(Suppl 4):100, 1989.
  54. Wolfe F: A brief clinical health assessment instrument: CLINHAQ. Arthritis Rheum 32(Suppl 4):C49, 1989.
  55. Wolfe F, Hawley DJ, Cathey MA: Health status measures over time: Serial assessment in 442 RA patients. Arthritis Rheum 32(Suppl 4):B85, 1989.
  56. Wolfe F, Hawley DJ, Cathey MA: Length of time on slow acting anti-rheumatic drugs (SAARDS): evidence for methotrexate effectiveness. Arthritis Rheum 32(Suppl 4):49a, 1989.
  57. Wolfe F, Hawley DJ, Cathey MA: Comparative effectiveness of slow acting anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum 32(Suppl 4):C48a, 1989.
  58. Hawley DJ, Wolfe F, Cathey MA: Psychometric properties of the sense of coherence questionnaire in subjects with rheumatic disease. Arthritis Rheum 33(Suppl 9), 1990.
  59. Wolfe F, Hawley DJ, Cathey MA, Roberts FK: Improvement in methotrexate treated RA patients is unrelated to disease severity. Arthritis Rheum 33(Suppl 9) S61, 1990.
  60. Cathey MA, Wolfe F, Roberts FK, Bennett RM, Caro X, Goldenberg DL, Russell IJ, Yunus MB: Demographic, work disability, service utilization and treatment characteristics of 620 fibromyalgia patients in rheumatologic practice. Arthritis Rheum 1990; 33:S10.
  61. Hochberg MC, Chang R, Dwosh I, Lindsey S, Pincus T, Wolfe F: Preliminary revised ACR criteria for functional status (FS) in rheumatoid arthritis (RA). Arthritis Rheum 33(Suppl 9) S15, 1990.
  62. Wolfe F, Hawley DJ, Cathey MA, Roberts K: The sense of coherence questionnaire in subjects with rheumatic disease. Arthritis Rheum 33(Suppl 9) S81, 1990.
  63. Wolfe F, Cathey MA, Hawley DJ, Roberts FK: The effect of age on methotrexate efficacy and toxicity. Arthritis Rheum 33(Suppl 9) S41,1990.
  64. Wolfe F, Simons D, Fricton J, Bennett RM, Goldenberg DL, Gerwin RD, Hathaway D, McCain GA, Russell IJ, Sanders H, Skootsky S: The fibromyalgia and myofascial pain syndromes: A study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. Arthritis Rheum 33 (Suppl 9) S137, 1990.
  65. Cannon GW, Kennedy SM, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L: Prospective three year follow-up of recombinant interferon-gamma in rheumatoid arthritis. Arthritis Rheum 33(Suppl 9) S25, 1990.
  66. Wolfe F, Cathey M.A., Roberts F.K.: The latex test revisited: Rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 34(Suppl 9) P10C, 1991.
  67. Hawley D.J., Wolfe F, Cathey M.A., Roberts F.K.: Marital status in rheumatoid arthritis. Arthritis Rheum 34(Suppl) P18C, 1991.
  68. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz P: Antecedents of mortality in rheumatoid arthritis (RA): A study of 1405 patients with RA in a community setting. Arthritis Rheum 1992;34: S48.
  69. Wolfe F, Cathey MA, Hawley DJ: Improvement in gold treated rheumatoid arthritis patients: A second look at gold effectiveness in the community. Arthritis Rheum 1991;34: S53.
  70. Wolfe F, Luggen M, Lane N: Radiographic abnormality and clinical status in osteoarthritis of the knee: An analysis of 332 cases. Arthritis Rheum 1991;34: S86.
  71. Cannon GW, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, Fay AM: Prospective five year follow-up of recombinant interferon-gamma in rheumatoid arthritis. Arthritis Rheum 1991;34: S91.
  72. Wolfe F, Mitchell DM, Sibley J, Fries JF, Bloch DA, Williams CA, Spitz P, Haga M, Kleinheksel SM, Cathey MA: The mortality of 3501 persons with rheumatoid arthritis in the ARAMIS data banks. Arthritis Rheum 1991;34: S182.
  73. Wolfe F, Mullis M, Cathey MA: A double blind placebo controlled trial of somatostatin in fibromyalgia. Arthritis Rheum 1991;34:S188.
  74. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA: The prognosis of RA & inflammatory polyarthritis (IPA) in the clinic. Arthritis Rheum 1992;35: S47.
  75. Hawley DJ, Wolfe F: Predictors of depression in rheumatoid arthritis. Arthritis Rheum 1992;35: A190.
  76. Wolfe F, Hawley DJ, Ross K: Addition of a pain drawing to a health status instrument improves patient care and clinical assessment. Arthritis Rheum 1992;35: B46.
  77. Raynauld JP, Bloch DA, Sibley JT, Wolfe F, Fries JA: Mortality from leukemia and lymphoma in rheumatoid arthritis (RA). Arthritis Rheum 1992;35.
  78. Wolfe F, Pincus T, ACT Committee on Health Care Research (COHCR): A clinical care and research database system for rheumatology. Arthritis Rheum 35 (Suppl), C62, 1992.
  79. Hawley DJ, Wolfe F: Depression is not more common in rheumatoid arthritis: A 10 year longitudinal study of 6,608 rheumatic disease patients. Arthritis Rheum 1992;35 (Suppl), C69.
  80. Raynauld JP, Bloch DA, Sibley JT, Wolfe F: Predictors of mortality in early vs. late rheumatoid arthritis. Arthritis Rheum 1992;35 (Suppl), C74.
  81. Wolfe F, Hawley DJ: The development of a disease status index (DSI) for rheumatoid arthritis. Arthritis Rheum 1992;35:S219.
  82. Wolfe F, Hawley DJ: The erythrocyte sedimentation rate (ESR) criterion in rheumatoid and osteoarthritis. Arthritis Rheum 1992;35 (Suppl), D76.
  83. Hawley DJ, Wolfe F: Depression in fibromyalgia: a comparative study of 1522 rheumatic disease patients. Scand J Rheumatol Suppl 1992; 45 (Suppl 94) 14(Abstract)
  84. Wolfe F: Fibromyalgia and Myofascial Pain. Lessons from the clinic and the community. Scand J Rheumatol. 1992; 21:(Sup 94) 7 (Abstract).
  85. Wolfe F, Ross K. Anderson J, Russell IJ: The meaning of tenderness: pain, tenderness and psychological status in the gene population. Arthritis Rheum 1993, (Abstract).
  86. Wolfe F, Anderson J, Ross K, Russell IJ: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1993; 36:S48 (Abstract).
  87. Raspe H, Baumgartner C, Wolfe F: The prevalence of fibromyalgia in a rural German community: How much difference do different criteria make? Arthritis Rheum 1993; 36 (Suppl), 58.
  88. Hawley DJ, Wolfe F: Does season and light affect pain and depression? A study of 2,566 arthritis patients. Arthritis Rheum 1993;36 (Suppl), 60.
  89. Cohen S, Rutstein J, Luggen M, Shergy W, Yocum D, Schnitzer TJ, Markenson J, Pincus T, Brooks R, Lisse J, Germain B, Bennett R, Wolfe F, Weisman M, Sonqcharoen S: Comparison of the safaety and efficacy of cyclosporine-A and methotrexate in refractory rheumatoid arthritis: A randomized, multi-centered, placebo-controlled trial. Arthritis Rheum 1993;36 (Suppl), 105.
  90. Wolfe F, Nietfeld S, Hedrick R, McElrath T, Ross K: Length of hospital stay and complications of total joint replacement are unrelated to functional status, pain, or psychological variables. Arthritis Rheum 1993; 36 (Suppl), 125.
  91. Carr AJ, Thompson PW, Wolfe F, Tugwell P, Kraeg G, Baker P, Groh J: Are there cultural differences in patient-perceived impact of chronic disease?: A survey of people with rheumatoid arthritis in Canada, USA and England. Arthritis Rheum 1993;36 (Suppl), A23.
  92. Wolfe F, Michaud K: The comparative long term effectiveness of second line anti-rheumatic (SAARD) therapy in rheumatoid arthritis. Arthritis Rheum 1993;36 (Suppl), B215.
  93. Wolfe F, Nietfled S, Hedrick R, McElrath T, Ross K: Gender difference and care for osteoarthritis: Differential severity for OA of the hip and knee as a function of gender. Arthritis Rheum 1993;36 (Suppl), B216.
  94. Rubin LA, McDermott M, Kastner DL, Amos DI, McDevitt HO, Holloman JD, Schmidt-Wolf G, Sinha AA, Lundberg AS, Cashin P, Molloy MG, Khan MA, Wolfe F, Clegg D, Ward R: The roll of T cell receptor ß chain haplotypes in conferring genetic susceptibility to rheumatoid arthritis. Arthritis Rheum 1993;36 (Suppl), C56.
  95. Raynauld JP, Wolfe F, Sibley JT, Fries JF: Mortality by cardiovascular disease and use of corticosteroids in rheumatoid arthritis. Arthritis Rheum 1993;36 (Suppl), C33.
  96. Wolfe F, Ross K, Anderson J: Tenderness, pain threshold, and their correlates in the general population. Arthritis Rheum 1993;36 (Suppl), S220.
  97. Wolfe F, Cathey MA, Hawley DJ: A double-blind placebo controlled trial of fluoxetine in patients with fibromyalgia. Arthritis Rheum 1993;36 (Suppl), C198.
  98. Wolfe F, Hawley DJ, Ross K, Anderson J: Depression is increased two-fold in RA and clinically significant arthritis. Arthritis Rheum 1993;36:S262.
  99. Wolfe F, Wilson K: The rate and consequences of adverse drug reactions in the clinic. Arthritis Rheum 1994;37 (Suppl), S197.
  100. Carr AJ, Thompson PW, Wolfe F: A cross-cultural comparison of patient-perceived handicap in USA and England using the disease repercussion profile. Arthritis Rheum 1994;37 (Suppl),S199.
  101. Wolfe F, Russell IJ: Serotonin levels, pain threshold and fibromyalgia symptoms in the general population. Arthritis Rheum 1994;37 (Suppl), S213.
  102. Wolfe F, Anderson J, Hawley DJ: Rates and predictors of work disability in rheumatoid arthritis: Importance of disease, psycho-social and workplace factors. Arthritis Rheum 1994;37 (Suppl), S231.
  103. Wolfe F, Riemsma RP, Taal E, Rasker JJ: The contribution of comorbidity to functional status and global health in patients with RA and OA. Arthritis Rheum 1994;37 (Suppl), S231.
  104. Wolfe F, Hawley DJ: Persisent inflammatory activity early in the course of RA predicts total joint replacement (TJR): A study of the rates, frequency and risk factors for TJR in RA. Arthritis Rheum 1994,37 (Suppl), S231
  105. Wolfe F, Altman R, Hochberg M, Lane N, Luggan M, Sharp J: Post menopausal estrogen therapy is associated with improved radiographic scores in OA & RA. Arthritis Rheum 1994,37 (Suppl), S231.
  106. Wolfe F, Anderson J, Ross K: Fibromyalgia symptoms and physical findings in persons with and without pain in the general population. Arthritis Rheum 1994,37 (Suppl), S349.
  107. Wolfe F, Hawley DJ: Toward an epidemiology of distress. Arthritis Rheum 1994,37 (Suppl), S350.
  108. Fries JF, Williams CA, Morfeld, Singh G, Wolfe F, Sibley J: Reduction in longterm disability in rheumatoid arthritis (RA) by DMARD-based treatment strategies. Arthritis Rheum 1994,37 (Suppl), S420.
  109. Williams CA, Bloch DA, Sibley J, Haga M, Wolfe F, Raynauld JP, Singh G, Hickey AR, Fries JF: Lymphoma and leukemia in rheumatoid arthritis: A matched case-control study in the ARAMIS (Arthritis, Rheumatism and Aging Medical Information System) population. Arthritis Rheum 1995, 38 (Suppl), 311.
  110. Symmons D, Jones M, Finn J, Wolfe F: Exposure to immunosuppressive therapy in rheumatoid arthritis increases the risk of death from malignancy but not from other causes. Arthritis Rheum 1995, 38 (Suppl), 313.
  111. Lane NE, Wolfe F: Estrogen therapy decreases the risk of osteoporotic fractures in RA patients on chronic glucocorticoids. Arthritis Rheum 1995, 38 (Suppl), 327.
  112. Wolfe F: C-Reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in rheumatoid arthritis (RA): Use in the clinic & for ACR criteria. Arthritis Rheum 1995, 38 (Suppl), 616.
  113. Peloso PM, Wolfe F, Hawley DJ, Wilson K, Anderson J: Back pain and knee OA - prevalence and correlates. Arthritis Rheum 1995, 38 (Suppl), 651.
  114. Mata S, Wolfe F, Joseph L, Esdaile JM: Absence of an association of rheumatoid arthritis (RA) and diffuse idiopathic skeletal hyperostosis (DISH): A case-control study. Arthritis Rheum 1995, 38 (Suppl), 656.
  115. Wolfe F: Silicone breast implants and the risk of fibromyalgia and rheumatoid arthritis. Arthritis Rheum 1995, 38 (Supp), 671.
  116. Wolfe F, Furst D, Lane N, Anderson J, Hawley DJ: Substantial increases in important adverse events follow low dose prednisone therapy in rheumatoid arthritis. Arthritis Rheum 1995, 38 (Suppl), 952.
  117. Wolfe F, Sharp JT: Long term radiographic outcome of patients seen early in the course of rheumatoid arthritis. Arthritis Rheum 1995, 38 (Suppl), 1056.
  118. Peloso PM, Wolfe F, Hawley DJ, Wilson K, Anderson J: The impact of back pain in rheumatoid arthritis. Arthritis Rheum 1995, 38 (Suppl), 1284.
  119. Wolfe F. What use are fibromyalgia control points? Arthritis Rheum 1997; 40 (Suppl) S43.
  120. Ehrich E, Schnitzler T, Kivitz A, Weaver A, Wolfe F, et al. MK-966 A hughly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6 week placebo controlled study. Arthritis Rheum 1997; 40 (Suppl) S330.
  121. DeWalt DA, Pincus T, Reed G, Callahan LF and Wolfe F. Differential diagnosis of rheumatoid arthritis (RA) versus diffuse non?inflammatory musculoskeletal pain (DNIMP): patient self?report questionnaire data , including a ratio of score of fatigue: activities of daily living (ADL) and number of symptoms appears as effective as the erythrocyte sedimentation rate (ESR). Arthritis Rheum 1997; 40 (Suppl) S114.
  122. Scudds BJ and Wolfe F.: A screening instrument for fibromyalgia (FS) in clinical and population studies. Arthritis Rheum 1997; 40 (Suppl) S117.
  123. Wolfe F.: Evidence of disordered symptom appraisal in fibromyalgia: increased rates of reported comorbidity and comorbidity severity. Arthritis Rheum 1997; 40 (Suppl) S117.
  124. Wolfe F, Pincus T, Fries JF, and the US Inception Cohort Group. Use of second line “Disease Modifying” Anti-Rheumatic Drugs (DMARDs) within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under the care of 142 US rheumatologist: an inception cohort study. Arthritis Rheum 1997; 40 (Suppl) S218.
  125. Wolfe F. and Johnston C: Rheumatoid factor and smoking: Evidence for a dose response independent of sex. Arthritis Rheum 1997; 40 (Suppl) S254.
  126. Wolfe F., Johnston C, Yee, B: Preliminary criteria for flare in rheumatoid arthritis. Arthritis Rheum 1997; 40 (Suppl) S312.
  127. Wolfe F. and Johnston C: Smoking is associated with premature development of rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1997; 40 (Suppl) S312.
  128. Wolfe F.: Increased rate of GI hospitalizations for RA patients compared to OA patients is explained by corticosteroid use. Arthritis Rheum 1997; 40 (Suppl) S313.
  129. Wolfe F.: Current GI symptoms are poor predictors of serious GI events in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1997; 40 (Suppl) S313
  130. Wofe, F.: A core set of domains for longitudinal observational studies in rheumatic disorders: consensus report from OMERACT 4. Arthritis Rheum 1998; 41 (Suppl)
  131. Wolfe F.: Back pain rather than radiographic abnormality explains WOMAC pain and function scores in patients with osteoarthritis and other rheumatic disorders. Arthritis Rheum 1998; 41 (Suppl)
  132. Wolfe F.: GI symptoms explain 24% of variance in quality of life (QOL) scores among patients with arthritis. Arthritis Rheum 1998; 41 (Suppl)
  133. Wolfe F.: Income, work status and utilization in early RA: the us inception cohort study. Arthritis Rheum 1998; 41 (Suppl)
  134. Wolfe F.: Methotrexate alters the course of rheumatoid arthritis (RA). Increased survival of methotrexate treated RA patients: a 25-year study of 1,842 patients. Arthritis Rheum 1998; 41 (Suppl)
  135. Wolfe F.: Predicting sf-36 scores from disease specific health status instruments. Arthritis Rheum 1998; 41 (Suppl)
  136. Wolfe F.: The national rheumatic disease data bank: case mix and severity characteristics of patients in rheumatological practice. Arthritis Rheum 1998; 41 (Suppl)
  137. Wolfe F.: What do rheumatologists do in their practices? Arthritis Rheum 1998; 41 (Suppl)
  138. Wolfe F.: Documentation of effective care of rheumatic diseases in routine clinical care using patient questionnaires. Arthritis Rheum 1998; 41 (Suppl)
  139. Wolfe F.: Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkins lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients. Arthritis Rheum 1998; 41 (Suppl)
  140. Wolfe F.: Modeling health related quality of life with generic and disease specific measures: use for clinic and research. Arthritis Rheum 1998; 41, S188 (Suppl)
  141. Wolfe F.: Modeling therapeutic strategies in rheumatoid arthritis: use of decision analysis and Markov models. Arthritis Rheum 1998; 41 (Suppl)
  142. PREDICTORS AND CONSEQUENCES OF ADVERSE DRUG REACTIONS (ADR) IN THE CLINIC. Frederick Wolfe and Sean Zhao. National Data Bank for Rheumatic Diseases, Wichita KS and Global Health Outcomes, G.D. Searle and Co, Skokie, IL. Arthritis Rheum 1999; 42 (Suppl).
  143. RADIOGRAPHIC METHODS IN KNEE OA ARE NOT THE SAME. SUPERIORITY OF THE MTP VIEW IN DETECTING JOINT SPACE NARROWING IN THE CLINIC. F Wolfe, N Lane, C Buckland-Wright. Wichita, San Francisco and London. Arthritis Rheum 1999; 42 (Suppl).
  144. PSYCHOLOGICAL FACTORS PRESENT AT DISEASE ONSET PREDICT SUBSEQUENT IMPROVEMENT: THE US INCEPTION COHORT STUDY. F Wolfe and S. Newman. Arthritis Research Center, Wichita KS 67214 and London, UK. Arthritis Rheum 1999; 42 (Suppl).
  145. A QUESTIONNAIRE-BASED DISEASE ACTIVITY SCALE (Q-DAS) FOR RHEUMATOID ARTHRITIS: RELATIONSHIP WITH HEALTH-RELATED QUALITY OF LIFE (QOL). Frederick Wolfe and Shelson X Kong. National Data Bank for Rheumatic Diseases, Wichita, KS 67214 and Whitehouse Station, NJ 08889. Arthritis Rheum 1999; 42 (Suppl).
  146. PREDICTING SERVICE UTILIZATION IN A NATIONAL SAMPLE OF RA PATIENTS WITH A QUESTIONNAIRE-BASED DISEASE ACTIVITY SCALE, THE Q?DAS. Frederick Wolfe and Sheldon X Kong. National Data Bank for Rheumatic Diseases and Merck & Co., Inc, Wichita, KS 67214 and Whitehouse Station, NJ 08889. Arthritis Rheum 1999; 42 (Suppl).
  147. DISEASE MODIFYING ANTIRHEUMATIC DRUGS (DMARD) AND DMARD COMBINATION USE BY 3604 PATIENTS OF 303 US RHEUMATOLOGISTS. F Wolfe, DJ Hawley, T Pincus. National Data Bank for Rheumatic Diseases. Wichita KS and Nashville TN. Arthritis Rheum 1999; 42 (Suppl).
  148. THE LONG-TERM OUTCOMES OF KNEE OA: RATES OF RADIOGRAPHIC PROGRESSION IN CLINICAL OA PATIENTS FOLLOWED FOR UP TO 26 YEARS. F Wolfe and N Lane. National Data Bank for Rheumatic Disease, Wichita KS and UCSF, San Francisco CA. Arthritis Rheum 1999; 42 (Suppl).
  149. THE RESULTS OF DMARD TREATMENT ON OVERALL OUTCOME OF RHEUMATOID ARTHRITIS IN A LARGE COHORT: SEQUENCE EFFECTS. Daniel A. Albert, Stacey Hurst, Michael Kallan, Frederick Wolfe, James F. Fries, University of Pennsylvania, Philadelphia, PA 19104. Arthritis Rheum 1999; 42 (Suppl).
  150. THE RESULTS OF DMARD TREATMENT ON OVERALL OUTCOME OF RA IN A LARGE COHORT: ESTIMATES OF RELATIVE DRUG EFFECTIVENESS. Daniel A Albert, Stacey Hurst, Michael Kallan, Frederick Wolfe, and James F. Fries, University of Pennsylvania, Philadelphia, PA 19104. Arthritis Rheum 1999; 42 (Suppl).
  151. ALL CAUSE AND CAUSE SPECIFIC MORTALITY IN RHEUMATOID ARTHRITIS (RA): A 25 YEAR STUDY OF 1,865 RA PATIENTS. F Wolfe, DJ Hawley and J Anderson. Arthritis Research Center and National Data Bank for Rheumatic Diseases, Wichita, KS 67214. Arthritis Rheum 1999; 42 (Suppl).
  152. CHARACTERISTICS OF PATIENTS BEGINNING A NEWLY RELEASED DMARD: EXPECTED RESPONSE AND PATIENT SELECTION. F Wolfe and DJ Hawley. National Data Bank for Rheumatic diseases, Wichita KS 67214. Arthritis Rheum 1999; 42 (Suppl).
  153. STANDARD VALUES FOR SELF-REPORT QUESTIONNAIRES: ASSESSMENTS IN 20,574 RHEUMATIC DISEASE PATIENTS. F Wolfe, DJ Hawley and T Pincus. National Data Bank for Rheumatic Diseases. Wichita KS and Nashville TN. Arthritis Rheum 1999; 42 (Suppl).
  154. THE ASSESSMENT OF FUNCTIONAL IMPAIRMENT IN FIBROMYALGIA: RASCH ANALYSES OF 5 FUNCTIONAL SCALES – FIQ, HAQ, MHAQ, IHAQ, SF-36 – AND THE DEVELOPMENT OF A NEW SCALE, THE FHAQ. F Wolfe, DJ Hawley, D Goldenberg, IJ Russell, D Buskila, L Neuman. Wichita, Boston, San Antonio, Beer Sheva. Arthritis Rheum 1999; 42 (Suppl).
  155. AN 8 ITEM INTERNATIONAL VERSION OF THE HAQ: THE INTER-HAQ. Tennant A, Ryser L*, Stucki G*, Wolfe F**. The Rheumatology and Rehabilitation Research Unit, University of Leeds, 36 Clarendon Road, Leeds, LS2 9NZ, UK;. * Zurich, Switzerland; **Wichita, USA. Arthritis Rheum 1999; 42 (Suppl).
  156. SUBSTANTIAL SUPERIORITY OF SEMI-FLEXED (MTP) VIEW IN KNEE OA: COMPARATIVE RADIOGRAPHIC STUDY, WITHOUT FLUOROSCOPY, OF EXTENDED, MTP AND SCHUSS VIEWS Chris Buckland-Wright, *Frederick Wolfe, Rupert Ward, *Nancy Flowers, Carol Hayne King's College, London SE1 9RT, UK; *Wichita, Kansas 67214, USA. Arthritis Rheum 1999; 42 (Suppl).
  157. ASSESSING RADIOGRAPHIC STATUS OF RHEUMATOID ARTHRITIS: INTRODUCTION OF A SHORTENED EROSION SCALE (SES). Frederick Wolfe, Désirée DM van der Heijde, Arvi Larsen, Wichita, Maastricht and Kongsvinger. Arthritis Rheum 1999; 42 (Suppl).
  158. PREFERENCE FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) OVER ACETAMINOPHEN BY RHEUMATIC DISEASE PATIENTS: A SURVEY OF 1799 PATIENTS WITH OSTEOARTHRITIS, RHEUMATOID ARTHRITIS AND FIBROMYALGIA. Frederick Wolfe, Sean Zhao and Nancy Lane. Arthritis Research Center and National Data Bank for Rheumatic Diseases, Global Health Outcomes - Searle and Co., UCSF, Wichita, Skokie and San Francisco. Arthritis Rheum 1999; 42 (Suppl).
  159. THE LONG TERM OUTCOMES OF FIBROMYALGIA: RATES AND PREDICTORS OF MORTALITY IN FIBROMYALGIA AFTER 25 YEARS OF FOLLOW-UP. F Wolfe, DJ Hawley, J Anderson. National Data Bank for Rheumatic Disease and Arthritis Research Center, Wichita, KS 67214. Arthritis Rheum 1999; 42 (Suppl).
  160. INFLAMMATION AS MEASURED BY THE ESR PREDICTS CARDIOVASCULAR MORTALITY ACROSS ALL RHEUMATIC DISORDERS: A 25-YEAR PROSPECTIVE STUDY 0F 5,822 PATIENTS. F Wolfe, DJ Hawley, J Anderson. National Data Bank for Rheumatic Disease and Arthritis Research Center, Wichita, KS 67214. Arthritis Rheum 1999; 42 (Suppl).
  161. TOWARD AN EPIDEMIOLOGY OF ADVERSE DRUG REACTIONS (ADR) AMONG RHEUMATIC DISEASE PATIENTS: ADR PREDICTORS AMONG 6412 RHEUMATIC DISEASE PATIENTS. F Wolfe, N Flowers, J Anderson, D Hawley. National Data Bank for Rheumatic Diseases and University of Kansas, Wichita KS USA 67214. EULAR, 2000.
  162. ADVERSE DRUG REACTIONS (ADR) TO NSAID THERAPY IN RHEUMATOID ARTHRITIS IS PREDICTED BY ADR TO DMARD AND CORTICOSTEROID TREATMENT: A STUDY OF 5,994 PATIENTS. F Wolfe and N Flowers. National Data Bank For Rheumatic Diseases and University of Kansas, Wichita KS USA 67214. EULAR, 2000.
  163. PATIENT QUESTIONNAIRE DATA DISCRIMINATE BETWEEN DRUG VERSUS PLACEBO AS EFFECTIVELY AS THE ACR20 IN A CLINICAL TRIAL OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA). Theodore Pincus, Frederick Wolfe, Vibeke Strand, Arthur Kavanaugh, Bruce Crawford, David Felson Nashville; Wichita; Stanford; San Diego and Boston. Arthritis Rheum 2000; 43 (Suppl).
  164. SOCIOECONOMIC AND DEMOGRAPHIC FACTORS ASSOCIATED WITH DRUG USE IN RHEUMATOID ARTHRITIS. Frederick Wolfe, Janice Anderson, Nancy Flowers Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  165. THE EFFECT OF PRIOR METHEOTREXATE (MTX) THERAPY ON RESPONSE TO LEFLUNOMIDE (LEF) IN PATIENTS WITH RHEUMATOID ARTHRITIS. F Wolfe Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  166. PREDNISONE AND FUNCTIONAL DISABILITY, NOT DMARDS OR BIOLOGICS, EXPLAIN INCREASED INFECTION RATES IN RHEUMATOID ARTHRITIS (RA). Frederick Wolfe, Nancy Flowers, Janice Anderson Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  167. RADIOGRAPHIC PROGRESSION PREDICTS SUBSTANTIAL INCOME LOSS AND WORK DISABILITY IN RHEUMATOID ARTHRITIS. Frederick Wolfe, Nancy Flowers, Janice Anderson Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  168. A PROGRAM CONCERNING PATIENT SELF-REPORT QUESTIONNAIRES ALTERS BELIEFS AND KNOWLEDGE OF US RHEUMATOLOGISTS. F Wolfe, T Pincus, S Cohen, V Strand, L Simon, P Tugwell, A K Thompson Wichita; Nashville; Dallas; Palo Alto; Boston; Ottawa and Kansas City. Arthritis Rheum 2000; 43 (Suppl).
  169. A FUNCTIONAL PROMOTER POLYMORPHISM IN MATRIX METALLOPROTEINASE 1 (MMP 1) IS ASSOCIATED WITH POOR OUTCOME IN RHEUMATOID ARTHRITIS. Smita Chitnis, Joanita Monteiro, Frederick Wolfe, Constance E Brinckerhoff, Peter K Gregersen, North American Rheumatoid Arthritis Consortium (NARAC) Manhasset, NY; Wichita, KS and Hanover, NH. Arthritis Rheum 2000; 43 (Suppl).
  170. NO ASSOCIATION BETWEEN RHEUMATOID ARTHRITIS AND/OR DMARD THERAPY AND HERPES ZOSTER: EVIDENCE FOR INDEPENDENT EFFECT OF PREDNISONE AND FUNCTIONAL DISABILITY ON ZOSTER DEVELOPMENT. Frederick Wolfe, Nancy Flowers, Janice Anderson Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  171. INCREASED PREVALENCE OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASE IN RHEUMATOID ARTHRITIS COMPARED WITH OSTEOARTHRITIS. Frederick Wolfe, Walter L Straus Wichita, KS and Whitehouse Station, NJ. Arthritis Rheum 2000; 43 (Suppl).
  172. HOSPITALIZATION RATES IN RHEUMATOID ARTHRITIS: EFFECT OF DISEASE DURATION, MEDICAL INSURANCE AND DISEASE SEVERITY. F Wolfe, N Flowers, J Anderson Wichita. Arthritis Rheum 2000; 43 (Suppl).
  173. THE KEY IMPORTANCE OF HOUSEHOLD INCOME AMONG DEMOGRAPHIC AND SOCIO-ECONOMIC VARIABLES IN RA. Frederick Wolfe, Nancy Flowers, Janice Anderson Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  174. COMPARATIVE SOCIO-ECONOMIC, CLINICAL AND OUTCOME STATUS OF MINORITY AND NON-MINORITY PATIENTS WITH RHEUMATOID ARTHRITIS. F Wolfe, N Flowers, J Anderson Wichita. Arthritis Rheum 2000; 43 (Suppl).
  175. DOES THE ACR/EULAR 28 JOINT COUNT OMIT IMPORTANT INFORMATION? A STUDY OF 22,744 JOINT EXAMINATIONS. F Wolfe, T Pincus Wichita and Nashville. Arthritis Rheum 2000; 43 (Suppl).
  176. THE RHEUMATOID ARTHRITIS PERCENTILE ACTIVITY SCORE (PAS): METHODS AND VALIDATION. F Wolfe, T Pincus Wichita and Nashville. Arthritis Rheum 2000; 43 (Suppl).
  177. ARE HEALTH-RELATED QUALTIY OF LIFE SCORES USEFUL IN PREDICTING THE USE OF HEALTH CARE SERVICES? EXPLORATION IN PATIENTS WITH ARTHRITIS. Olivier Ethgen, Kristijan H Kahler, Sheldon X Kong, Jean-Yves Reginster, Frederick Wolfe Liege, Belgium; Whitehouse Station, NJ and Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  178. WHICH HAQ IS BEST? A COMPARISON OF THE HAQ, MHAQ AND RA-HAQ IN 2491 RA PATIENTS FOLLOWING LEFLUNOMIDE INITIATION. Frederick Wolfe Wichita, KS. Arthritis Rheum 2000; 43 (Suppl).
  179. POOR OUTCOME AND NON-RESPONSE TO DMARD THERAPY: A STUDY OF 6870 RHEUMATOID ARTHRITIS PATIENTS. F Wolfe, T Pincus Wichita, KS and Nashville, TN. Arthritis Rheum 2000; 43 (Suppl).
  180. STATISTICAL OR CLINICAL SIGNIFICANCE: TRANSLATING THE ACR IMPROVEMENT CRITERIA INTO MEANINGFUL NUMBERS. F Wolfe, T Pincus Wichita and Nashville. Arthritis Rheum 2000; 43 (Suppl).
  181. Wolfe F. Can ACR improvement criteria be used in the clinic to demonstrate response to therapy? Arthritis Rheum 2001; 44 (Suppl).
  182. Wolfe F, Choi HK. Predicting outcome in RA: which variables are best? Arthritis Rheum 2001; 44 (Suppl).
  183. Choi HK, Wolfe F. Radiologic progression and mortality. Arthritis Rheum 2001; 44 (Suppl).
  184. Fries JF, Wolfe F, Apple R, Erlich H, Holmes T, Bruce B, Drb1 genotypes in 952 inception cohort patients with rheumatoid arthritis( RA) : frequency and severity associations in 21 groups. Arthritis Rheum 2001; 44 (Suppl).
  185. Wolfe F, Messer J. The direct medical costs of rheumatoid arthritis in 1999-2000. Arthritis Rheum 2001; 44 (Suppl).
  186. Wolfe F, Reynolds M, Burke TA, Zhao S. Hypertension and hypertension associated adverse events (AEs). Among 6,673 celecoxib, rofecoxib, non-specific (NS) NSAID, and non-NSAID users receiving ordinary clinical care. Arthritis Rheum 2001; 44 (Suppl).
  187. Wolfe F, Reynolds M, Burke TA, Zhao S. Edema and edema associated adverse events (AEs) among 6,673 celecoxib, rofecoxib, non-specific ns. NSAID, and non-NSAID users receiving ordinary clinical care. Arthritis Rheum 2001; 44 (Suppl).
  188. Wolfe F, Reynolds M, Burke TA, Zhao S, Pettit D. Anti-inflammatory drug discontinuation in arthritis clinical practice: a comparison of NSAIDs, celecoxib, and rofecoxib. Arthritis Rheum 2001; 44 (Suppl).
  189. Wolfe F, Messer J. Disease severity, treatment, demographics and the risk of hospitalization in RA. Arthritis Rheum 2001; 44 (Suppl).
  190. Wolfe F. Pain and diagnosis in fibromyalgia: development and validation of the regional pain scale (RPS) in 12,799 rheumatic disease patients. Arthritis Rheum 2001; 44 (Suppl).
  191. Wolfe F, Flowers N, Anderson J, Urbansky K. Tuberculosis rates are not increased in rheumatoid arthritis (RA). Arthritis Rheum 2001; 44 (Suppl).
  192. Choi HK, Hernan M, Seeger J, Robins J, Wolfe F. Mortality benefit of methotrexate: overcoming confounding by indication. Arthritis Rheum 2001; 44 (Suppl).
  193. Duryea J, Zaim S, Wolfe F. Computerized radiographic scoring of the joints of the wrist to assess rheumatoid arthritis. Arthritis Rheum 2001; 44 (Suppl).
  194. Pincus T, Sokka T, Wolfe F. A visual analog pain scale on a multi-dimensional health assessment questionnaire (MDHAQ) is as sensitive as the WOMAC to document efficacy of diclofenac/misoprostol (arthrotec) compared to acetaminophen (ACETA) in a randomized controlled crossover clinical trial. Arthritis Rheum 2001; 44 (Suppl).
  195. Wolfe F, Stephenson B, Doyle, J. RA patients remain on leflunomide as long as methotrexate in clinical practice: accumulating evidence of long-term tolerability and effectiveness of leflunomide in RA. Arthritis Rheum 2001; 44 (Suppl).
  196. Wolfe F, Stephenson B, Doyle, J. The number of previous DMARDs best predicts success of leflunomide therapy. Arthritis Rheum 2001; 44 (Suppl).
  197. Wolfe F, Flowers N, Urbansky K. The effect of health-related work limitations on the income of employed adults with rheumatoid arthritis (RA). Arthritis Rheum 2001; 44 (Suppl).
  198. Wolfe F, Choi HK. Ra patients with radiographic progression are at increased risk for total joint replacement, even after controlling for disease activity and disease severity. Arthritis Rheum 2001; 44 (Suppl).
  199. Pincus T, F Wolfe F, Strand V, Cohen S, Crawford B, Felson D. A pooled index of patient questionnaire data discriminates between responses to leflunomide (LEF) or methotrexate (MTX) vs placebo at a 20% level as effectively as the disease activity index (DAS), ACR20), pooled index of non-patient questionnaire measures, or all 7 core data set measures in a clinical trial of patients with rheumatoid arthritis (RA). Arthritis Rheum 2001; 44 (Suppl).
  200. Wolfe F, Sesti AM. The effect of health-related work limitations on the income of employed adults with fibromyalgia. Arthritis Rheum 2001; 44 (Suppl).
  201. Frederick Wolfe, Kaleb Michaud. Work Disability in a National Sample of RA Patients in Patients with Rheumatic. Arthritis Rheum 2002; 46 (Suppl).
  202. Hyon K Choi, Kaleb Michaud, Fredrick Wolfe. Utility Measures in Rheumatic Disorders. Arthritis Rheum 2002; 46 (Suppl).
  203. Frederick Wolfe, Kaleb Michaud, Tilly Mylonas, David Purdie, Nirmala Pandeya, Andreas Suhrbier. Tracking an Epidemic Illness with Self-Report Questionnaires: Ross River Virus Epidemic Polyarthritis. Arthritis Rheum 2002; 46 (Suppl).
  204. N Lane, F Wolfe, J Sibley, M Luggen, J Oehlert, B Lingala, J Fries. A Longitudinal Observational Study of Progression of Knee and Hip Osteoarthritis (OA): Preliminary Results on the Relationship to NSAID Use. Arthritis Rheum 2002; 46 (Suppl).
  205. Frederick Wolfe, Kaleb Michaud, Gregory Keenan, Peter Callegari. The Safety of Disease Modifying Anti Rheumatic Drugs and Biologic Therapy (DBT) in Rheumatoid Arthritis. Arthritis Rheum 2002; 46 (Suppl).
  206. Frederick Wolfe, Kaleb Michaud, Sean Z Zhao, Thomas A Burke, Dan Pettitt. Satisfaction and Preferences for NSAIDs and COX-2 Specific Inhibitors among Patients with Rheumatoid Arthritis. Arthritis Rheum 2002; 46 (Suppl).
  207. N Lane, F Wolfe, J Sibley, M Luggen, J Oehlert, B Lingala, J Fries. Does Non-Steroidal Antiinflammatory Drug ( Nsaid) Treatment Accelerate the Progression of Osteoarthritis (OA): Preliminary Results of a Randomized Control Trial of NSAIDS and Acetaminophen (APAP). Arthritis Rheum 2002; 46 (Suppl).
  208. Theodore Pincus, John G Fort, Gary Koch, Fred Wolfe, Roland W Moskowitz, Stephen Zlotnick, Lee S Simon, Allan Gibofsky, Hau Lei, Reinhard Schuller. Preference of Patients with Osteoarthritis of the Hip or Knee for Celecoxib versus Acetaminophen and Placebo in a Randomized, Double-Blind, Cross-Over Clinical Trial. Arthritis Rheum 2002; 46 (Suppl).
  209. Frederick Wolfe, Kaleb Michaud, Jodi Messer. The Characteristics and Patterns of Analgesic use in Rheumatoid Arthritis. Arthritis Rheum 2002; 46 (Suppl). Arthritis Rheum 2002; 46 (Suppl).
  210. Frederick Wolfe, Kaleb Michaud. Toward an Acceptable Definition of DMARD Failure and Abnormal Health Status in RA. Arthritis Rheum 2002; 46 (Suppl).
  211. Frederick Wolfe, Kaleb Michaud, Sean Z Zhao, Thomas A Burke, Dan Pettitt. Toward an Epidemiology of NSAID and COX-2 Specific Inhibitor Efficacy Equivalence. Arthritis Rheum 2002; 46 (Suppl).
  212. Frederick Wolfe. The Measurement of Fatigue in Rheumatoid Arthritis. Arthritis Rheum 2002; 46 (Suppl).
  213. Frederick Wolfe, Kaleb Michaud, Jodi Messer. The Epidemiology of GI Drugs Use Among Persons with RA, OA and Fibromyalgia. Arthritis Rheum 2002; 46 (Suppl).
  214. Frederick Wolfe. Low Rates of Serious Liver Toxicity to Leflunomide (LEF) and Methotrexate (MTX): A Longitudinal Surveillance Study of 14,997 LEF and MTX Exposures in RA. Arthritis Rheum 2002; 46 (Suppl).
  215. Frederick Wolfe, Kaleb Michaud, Gregory Keenan, Peter Callegari, Mohan Bala. Measurement of Infliximab Effectiveness in Clinical Practice. Arthritis Rheum 2002; 46 (Suppl).
  216. Frederick Wolfe, Kaleb Michaud, Joseph Doyle, Barbara Stephenson. Toward a Definition and Method of Assessment of Treatment Failure and Treatment Effectiveness: The Case of Leflunomide Versus Methotrexate. Arthritis Rheum 2002; 46 (Suppl).
  217. Kathy Urbansky, Terry Sanford, Kaleb Michaud, Gregory Keenan, Peter Callegari, Frederick Wolfe. Safety Data from a Registry of Patients Receiving Infliximab – Preliminary Report After 1 Year. Arthritis Rheum 2002; 46 (Suppl).
  218. Kaleb Michaud, Jodi Messer, Hyon K Choi, Frederick Wolfe. The Economic Consequences of Changes in Disease Activity, Functional Status, and Utility Measure in Patients with Rheumatoid Arthritis. Arthritis Rheum 2002; 46 (Suppl).
  219. Jodi Messer, Kaleb Michaud, Hyon K Choi, Frederick Wolfe. Lifetime Direct Medical Costs of Rheumatoid Arthritis. Arthritis Rheum 2002; 46 (Suppl).
  220. K. Michaud, A. Mendelsohn, and F. Wolfe. Congestive Heart Failure in Rheumatoid Arthritis: Rates, Predictors and the Effect of Anti-TNF Therapy. Ann Rheum Dis; 99, 2003. (Abstract)
  221. K. Michaud1, F. Wolfe [OP0095] REDUCED MORTALITY AMONG RA PATIENTS TREATED WITH ANTI-TNF THERAPY AND METHOTREXATE. Ann Rheum Dis; 64, 2005. (Abstract)
  222. A. Finckh, H.K. Choi , K. Michaud , F. Wolfe. PROGRESSION OF RADIOGRAPHIC JOINT DAMAGE IN DIFFERENT ERAS. HAS RHEUMATOID ARTHRITIS BECOME A MILDER DISEASE OVER THE PAST DECADES? Ann Rheum Dis; 64, 2005.
  223. F. Wolfe, K. Michaud. LUNG CANCER AND RA: NO ASSOCIATION AFTER ADJUSTMENT FOR NON-RA FACTORS. Ann Rheum Dis; 64, 2005.
  224. F. Wolfe, K. Michaud. LONGITUDINAL ASSESSMENT OF PAIN IN RA: MCID, PREDICTORS AND THE EFFECT OF OF ANTI-TNF THERAPY. Ann Rheum Dis; 64, 2005.
  225. R. Westhovens, F. Wolfe , M.U. Rahman , J. Han , D. Yocum. INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE START TRIAL. Ann Rheum Dis; 64, 2005.
  226. F. Wolfe, K. Michaud. BREAST CANCER IN RA: NO EFFECT OF ANTI-RHEUMATIC THERAPY. Ann Rheum Dis; 64, 2005.
  227. F Wolfe, K Michaud, T Pincus, A Pangan, J Kent. Usefulness of a Visual Analog Function Scale in RA Clinical Trials: Increased Sensitivity Compared with Conventional Measures. Arthritis Rheum 52: 2005 (Supplement).
  1. Roxabella Torres, F Wolfe, K Michaud. Rheumatoid Arthritis, Medical Costs, Access to Care and the Outcome of Illness. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Combination Therapy and the Outcome of Rheumatoid Arthritis (RA). Arthritis Rheum 52: 2005 (Supplement).
  1. K Michaud, F Wolfe. Reduced Mortality among RA Patients Treated with Anti-TNF Therapy and Methotrexate. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud, T Simon. Can Severity be Predicted in Rheumatoid Arthritis Administrative Data Bases? Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Lung Cancer and RA: No Association after Adjustment for Non-RA Factor. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Breast Cancer in RA: No Effect of Anti-Rheumatic Therapy. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Rates of GI Bleeding and Perforated Ulcers, and Changing Patterns of Risk Factors. Arthritis Rheum 52: 2005 (Supplement).
  1. EM DeWitt, HA Glick, DA Albert, MM Joffe, F Wolfe. Medicare Coverage of TNF-Alpha Inhibitors Influences Prescribing Behavior. Arthritis Rheum 52: 2005 (Supplement).
  1. RS Katz, F Wolfe, K Michaud. How Shall Fibromyalgia be Diagnosed? A Comparison of Clinical, Survey and ACR Criteria. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, RS Katz, K Michaud. Toward a General Measure of Fibromyalgia Symptomatology: The Fibromyalgia Intensity (FI) Scale. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, Robert S. Katz, K Michaud. The Risk of Fibromyalgia Development: Rates and Risk Factors. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud, Tracy Li. A Comparision of the Medical Outcomes Study (MOS) Sleep Scales with a Visual Analogue Sleep Disturbance Scale in Patients with Rheumatoid Arthritis (RA). Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Prevalence and Characteristics of Anemia in Patients with Rheumatoid Arthritis (RA). Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud, T Pincus, A L. Pangan, J Kent. An Effective Measure of Treatment Efficacy: The VAS Stiffness Severity Scale: Results from the Humira Efficacy Response Optimization (HERO) Trial. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Longitudinal Assessment of Pain in RA: MCID, Predictors and the Effect of Anti-TNF Therapy. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Duration of Leflunomide and Biologic Therapies: Switching Behavior and Predictors of Discontinuation. Arthritis Rheum 52: 2005 (Supplement).
  1. K Michaud, F Wolfe. EQD Changes Rheumatoid Arthritis Quality of Life in United States: A Retrospective Study of 11,289 Patients. Arthritis Rheum 52: 2005 (Supplement).
  1. E Benito-Garcia, F Wolfe. Quality of life among Portuguese workers with rheumatoid arthritis. Arthritis Rheum 52: 2005 (Supplement).
  1. E Benito-Garcia, F Wolfe. Work disability among persons with rheumatoid arthritis in Portugal. Arthritis Rheum 52: 2005 (Supplement).
  1. L Colglazier, F Wolfe, K Michaud. Rheumatoid Arthritis (RA) Patients are Less Likely to be Treated with Prophylactic Aspirin Despite an Increased Risk of Myocardial Infarction. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, AS Russell. Once on Prednisone Always on Prednisone? Rates and Reasons for Prednisone Use and Predictors of Discontinuation. Arthritis Rheum 52: 2005 (Supplement).
  1. JD Kent, AL. Pangan, F Wolfe, MJ. Hufford. Real-Time Data Capture on Treatment Response: Preliminary Results from the HUMIRA® Efficacy Response Optimization (HERO) Study in Patients with Active Rheumatoid Arthritis. Arthritis Rheum 52: 2005 (Supplement).
  1. JD Kent, AL. Pangan, F Wolfe, MJ. Hufford. Diurnal Variation of Pain, Fatigue, Function and Disease Activity in Patients with Active Rheumatoid Arthritis: Preliminary Results from the Humira® Efficacy Response Optimization (HERO) Study. Arthritis Rheum 52: 2005 (Supplement).
  1. F Wolfe, K Michaud. Outcomes in RA Patients Not Meeting Severity Criteria for Biologic Prescription. Arthritis Rheum 2006; 54.
  1. S Allaire, F Wolfe, J Niu, MP LaValley.Lost Productivity and Underemployment in Employed Persons with Rheumatoid Arthritis (RA). Arthritis Rheum 2006; 54.
  1. K Michaud, F Wolfe. Longitudinal Changes in Quality of Life in Rheumatoid Arthritis Compared with a Healthy US National Sample. Arthritis Rheum 2006; 54.
  1. K Michaud, F Wolfe,Health Status of Arthritis Patients who Discontinued Rofecoxib. Arthritis Rheum 2006; 54.
  1. F Wolfe, K Michaud, T Pincus, J D Kent, A L Pangan. Clinical Response by Day with Adalimumab in Patients with Active Rheumatoid Arthritis: Humira Efficacy Response Optimization (HERO) Study. Arthritis Rheum 2006; 54.
  1. F Wolfe, K Michaud, T Pincus, J D Kent, A L Pangan. Utility of Patient-Reported Outcomes in Assessing Treatment Response in Rheumatoid Arthritis: Humira® Efficacy Response Optimization (HERO) Trial. Arthritis Rheum 2006; 54.
  1. F Wolfe, K Michaud. The Use of Biologic Therapy in Patients with RA and Existing Cancer. Arthritis Rheum 2006; 54.
  1. F Wolfe, K Michaud. Resistance to Changing Therapy: Discordance Between RA Activity and Patients' Treatment Choices. Arthritis Rheum 2006; 54.
  1. R S Katz, F Wolfe, K Michaud, C M Cooney. The Association of Fibromyalgia Symptoms with SLE Outcome and Diagnosis. Arthritis Rheum 2006; 54.
  1. F Wolfe, K Michaud. The Association of New Cases of Cancer with Biologic Therapy. Arthritis Rheum 2006; 54.
  1. F Wolfe, R Katz, K Michaud. Economic Inequalities and Reduced Quality of Life in Patients with Osteoarthritis and Fibromyalgia. Arthritis Rheum 2006; 54.
  1. S Allaire, F Wolfe, J Niu, MP LaValley. Contemporary Data on Work Disability Associated with Rheumatoid Arthritis (RA). Arthritis Rheum 2006; 54.
  1. P J Nietert, K Michaud, F Wolfe. Differential Item Functioning in the Health Assessment Questionnaire: Analyses Focused on Gender and Race Among Patients With Rheumatoid Arthritis. Arthritis Rheum 2006; 54.

The following were published in Arthritis and Rheumatism and presented at the 2007 ACR Annual Meeting.

  1. Gesa Neumann1, Paola dePablo1, Axel Finckh2, Lori B. Chibnik1, Frederick Wolfe3, Jeffrey Duryea1. 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 2University of Geneva, Geneva, Switzerland; 3National Data Bank for Rheumatic Diseases, Wichita, KS.Long term Patient Repositioning Reproducibility of Joint Space Width (JSW) Measurements on Hand Radiographs
  1. Jeffrey Duryea1, Carl Winalski2, Frederick Wolfe3, Lori B. Chibnik1. 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 2Cleveland Clinic, Cleveland, OH; 3National Data Bank for Rheumatic Diseases, Wichita, KS.Software Tool to Score Erosions on Digital Hand Radiographs for Rheumatoid Arthritis Assessment
  1. Timothy Shaver1, Shadi Shahouri1, James Anderson1, David Weidensaul1, Ruth Busch1, Kaleb Michaud2, Frederick Wolfe3. 1Arthritis and Rheumatology Clinics of Kansas, Wichita, KS; 2University of Nebraska Medical Center, Omaha, NE; 3National Data Bank for Rheumatic Diseases, Wichita, KS.The Outcome of Aggressive Biologic Therapy in Clinical Practice: Measurement by DAS Remission and Minimal Disease Activity (MDA).
  1. Teresa Simon1, Kaleb Michaud2, Kimberly Ray1, Frederick Wolfe3. 1Global Epidemiology, Bristol-Myers Squibb, Hopewell, NJ; 2University of Nebraska Medical Center, Omaha, NE; 3National Data Bank for Rheumatic Diseases, Wichita, KS.Contemporary Use of Abatacept in Rheumatoid Arthritis
  1. Frederick Wolfe1, Kaleb Michaud2, Michael Luggen3. 1National Data Bank for Rheumatic Diseases, Wichita, KS; 2University of Nebraska Medical Center, Omaha, NE; 3University of Cincinnati Medical Center, Cincinnati, OH.The Effectiveness and Cost-Effectiveness of Anti-TNF Therapy in the Community
  1. Montserrat Vera-Llonch1, Elena Massarotti2, Nancy Shadick3, Frederick Wolfe4, Rene Westhovens5, Ross Maclean6, Tracy Li6, Gerry Oster1. 1Policy Analysis Inc. (PAI), Brookline, MA; 2Tufts-New England Medical Center, Boston, MA; 3Brighams & Women's Hospital, Boston, MA; 4National Data Bank for Rheumatic Diseases, Wichita, KS; 5University Hospital, Katholieke University, Leiden, Belgium; 6Bristol-Myers Squibb, Princeton, NJ.Cost-Effectiveness of Abatacept in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Tumor Necrosis Factor a Inhibitors
  1. Hal Hoffman1, Scott Mellis2, Imogene Grimes2, Pavel Belomestnov2, Rebecca Schumacher3, Kimberly Harp3, David Stein2, Fred Wolfe3. 1UCSD Division of Rheumatology,Allergy and Immunology, La Jolla, CA; 2Regeneron Pharmaceuticals, Tarrytown, NY; 3Data Bank for Rheumatic Diseases, Wichita, KS.Variability of Disease Activity in Cryopyrin-Associated Periodic Syndromes (CAPS): Design of a Daily Health Assessment Form (DHAF) for Clinical Research
  1. Frederick Wolfe1, Saralynn Allaire2, Kaleb Michaud3. 1National Data Bank for Rheumatic Diseases, Wichita, KS; 2Boston University, Boston, MA; 3University of Nebraska Medical Center, Omaha, NE.The Prevalence, Incidence, and Effect of Anti-Tumor Necrosis Factor (TNF) on Work Disability in Rheumatoid Arthritis
  1. Kaleb Michaud1, Ted R. Mikuls1, James R. O'Dell1, Kevin L. Garvin1, Edward V. Fehringer1, Frederick Wolfe2. 1University of Nebraska Medical Center, Omaha, NE; 2National Data Bank for Rheumatic Diseases, Witchita, KS.The Impact of Total Knee Replacement (TKR) on Patient Reported Pain and Health-Related Quality of Life in Subjects with Rheumatoid Arthritis (RA)
  1. Eliza F. Chakravarty1, Kaleb Michaud2, Frederick Wolfe3. 1Stanford University, Palo Alto, CA; 2University of Nebraska Medical Center, Omaha, NE; 3National Data Bank for Rheumatic Diseases, Wichita, KS.Diverticular Disease in Rheumatoid Arthritis
  1. Frederick Wolfe1, Kaleb Michaud2. 1National Data Bank for Rheumatic Diseases, Wichita, KS; 2University of Nebraska Medical Center, Omaha, NE.Duration of Use of Anti-TNF Therapy in Rheumatoid Arthritis
  1. Kaleb Michaud1, Robert Katz2, Michelle Petri3, Graciela S. Alarcón4, Eliza Chakravarty5, John Goldman6, Frederick Wolfe7, The Systemic Lupus Erythematosus in the CommunityStudy Group. 1University of Nebraska Medical Center, Omaha, NE; 2Rush Medical Center, Chicago, IL; 3John Hopkins University, Baltimore, MD; 4University of Alabama at Birmingham, Birmingham, AL; 5Stanford University, Stanford, CA; 6Emory University, Atlanta, GA; 7National Data Bank for Rheumatic Diseases, Wichita, KS.The Characteristics of a Systemic Lupus Erythematosus (SLE) National Cohort
  1. Kaleb Michaud1, Frederick Wolfe2. 1University of Nebraska Medical Center, Omaha, NE; 2National Data Bank for Rheumatic Diseases, Wichita, KS.Patterns of Comorbidity in Rheumatic Disorders
  1. T. A. Simon1, A. L. Smitten2, M. Meng1, S. Suissa3, for the Epidemiology Study Group, J. Askling4, J. Franklin5, M. Hochberg6, D. Lacaille7, F. Wolfe8. 1Bristol-Myers Squibb, Hopewell, NJ; 2Duke Univ Sch of Med, Durham, NC; 3McGill Univ, Montreal, QC, Canada; 4Karolinska Inst, Stockholm, Sweden; 5ARC Epidem Unit, Manchester, United Kingdom; 6Univ of Maryland, Baltimore, MD; 7Univ of British Columbia, Vancouver, BC, Canada; 8Nat'l Data Bank for Rheum Diseases, Wichita, KS.Observed and Expected Malignancies in the Rheumatoid Arthritis Abatacept Clinical Development Program: An Updated Epidemiological Assessment
  1. T. A. Simon1, A. L. Smitten2, M. Meng1, for the Epidemiology Study Group, J. Franklin3, J. Askling4, D. Lacaille5, F. Wolfe6, S. Suissa7, M. Hochberg8. 1Bristol-Myers Squibb, Hopewell, NJ; 2Duke Univ School of Medicine, Durham, NC; 3ARC Epidemiology Unit, Manchester, United Kingdom; 4Karolinska Institute, Stockholm, Sweden; 5Univ of British Columbia, Vancouver, BC, Canada; 6National Data Bank for Rheumatic Diseases, Wichita, KS; 7McGill Univ, Montreal, QC, Canada; 8Univ of Maryland, Baltimore, MD.Observed and Expected Hospitalized Infections in the Abatacept Clinical Development Program: An Updated Epidemiological Assessment
  1. Hye-Soon Lee1, Wentian Li1, Annette Lee1, Franak Batliwalla1, Frederick Wolfe2, Robert M. Plenge3, Michael F. Seldin4, Christopher I. Amos5, Daniel L. Kastner6, Lindsey A. Criswell7, Peter K. Gregersen1. 1The Feinstein Institute for Medical Research, Manhasset, NY; 2National Data Bank for Rheumatic Diseases, Wichita, KS; 3Broad Institute of MIT and Harvard, Cambridge, MA; 4Department of Biochemistry and Molecular Medicine, Rowe Program in Human Genetics, University of California, Davis, CA; 5Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; 6National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD; 7Department of Medicine, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA.Fine Mapping across the MHC with 2,095 SNPs Identifies at least Two Regions of Susceptibility Independent of the DRB1 Locus
  1. Hal Hoffman1, Fred Wolfe2, Arthur Kavanaugh1, Alan Kivitz3, Imogene Grimes4, Steve Weinstein4, Scott Mellis4. 1UCSD Division of Rheumatology,Allergy and Immunology, La Jolla, CA; 2University of Kansas, Wichita, KS; 3Altoona Center for Clinical Research, Duncansville, PA; 4Regeneron Pharmaceuticals, Tarrytown, NY.Sustained Efficacy of Rilonacept (IL-1 Trap) in Patients with Cryopyrin-Associated Periodic Syndromes (CAPS)
  1. Frederick Wolfe1, Kaleb Michaud2. 1National Data Bank for Rheumatic Diseases, Wichita, KS; 2University of Nebraska Medical Center, Omaha, NE.The Effect of Rheumatic Disease Treatment on the Risk of Myocardial Infarction: Increased Risk from Rofecoxib, Valdecoxib and Celecoxib; Decreased Risk from Anti-TNF Therapy
  1. Damandeep S. Walia1, Harchetan Singh1, Kate Jennings1, Fred Wolfe2, Barbara P. Lukert1, Donald D. Smith1, Ernesto N. Levy3, Kent A. Huston4, Herbert B. Lindsley1. 1University of Kansas Medical Center, Kansas City, KS; 2University of Kansas School of Medicine, Wichita, KS; 3Penn State/Div Rheum HO38, Hershey, PA; 4Center for Rheumatic Diseases, Kansas City, MO. Prevalence with Seasonal Variation of Hypovitaminosis D, and Male Hypogonadism, in Prednisone-treated Patients with Rheumatic Disease
  1. Robert Katz1, Kaleb Michaud2, Frederick Wolfe3. 1Rush Medical Center, Chicago, IL; 2University of Nebraska Medical Center, Omaha, NE; 3National Data Bank for Rheumatic Diseases, Wichita, KS. Fibromyalgia Patients Reading Self-Help Journals and in Internet Self-Help Groups: Are They Different from Patients in Clinical Practice?
  1. Robert Katz1, Michelle Petri2, Elizabeth W. Karlson3, Graciela S. Alarcón4, Eliza Chakravarty5, John Goldman6, Frederick Wolfe7, Systemic Lupus Erythematosus in the Community Study Group. 1Rush Medical Center, Chicago, IL; 2John Hopkins University, Baltimore, MD; 3Brigham and Women's Hospital, Boston, MA; 4University of Alabama at Birmingham, Birmingham, AL; 5Stanford University, Stanford, CA; 6Emory University, Atlanta, GA; 7National Data Bank for Rheumatic Diseases, Wichita, KS.Performance of the SLAQ in SLE and Non-SLE Subjects in a Longitudinal Databank
  1. Kaleb Michaud1, Frederick Wolfe2. 1University of Nebraska Medical Center, Omaha, NE; 2National Data Bank for Rheumatic Diseases, Wichita, KS.The Development of a Rheumatic Disease Research Comorbidity Index for Use in Outpatients with RA, OA, SLE and Fibromyalgia (FMS)
  1. Martha L. Sanchez1, Karen H. Costenbader2, Elizabeth W. Karlson2, Graciela S. Alarcón1, Frederick Wolfe3. 1University of Alabama at Birmingham, Birmingham, AL; 2Lupus Center Brigham and Women's Hospital, Boston, MA; 3National Data Bank for Rheumatic Diseases, Wichita, KS.Is it Possible to Ascertain Damage in Lupus Utilizing a Self-Reported Questionnaire? Preliminary Data on the Lupus Damage Index Questionnaire (LDIQ)
  1. Saralynn Allaire1, Frederick Wolfe2, Jingbo Niu1, Michael LaValley3. 1Boston University School of Medicine, Boston, MA; 2National Data Bank for Rheumatic Diseases, Wichita, KS; 3Boston University School of Public Health, Boston, MA.No Evidence of Reduction in Premature Work Loss among Persons with Rheumatoid Arthritis (RA) Using Anti-TNF Alpha Agents

    The following were presented at the 2008 American College of Rheumatology meeting.

  1. Measuring the Burden of Out of Pocket Expenses in Patients with Rheumatic Diseases: Usefulness of the Out of Pocket Burden (OPB) Scale. Frederick Wolfe, Kaleb Michaud.
  2. Prevalence, Incidence and Predictors of Depression in Rheumatoid Arthritis. Frederick Wolfe, Kaleb Michaud.
  1. Predictors Of Quality Of Life In Rheumatoid Arthritis Patients With Earlier And Later Disease. Elizabeth Benito-Garcia, Sofia Ramiro, Sofia Pedro, Rita Marques, Frederick Wolfe, Kaleb Michaud.
  1. Societal Costs and Disability Impact in Rheumatic Diseases. Frederick Wolfe, Kaleb Michaud, Robert S. Katz.
  1. High Unmet Need for Arthritis Pain Management Among EU and US Rheumatoid Arthritis Patients Despite Effective Therapies. Peter Taylor, Arthur Kavanaugh, Frederick Wolfe, Juan Gomez-Reino, Elisabeth Eberhardt.
  1. Patients With Rheumatoid Arthritis Have Better Quality Of Life When Not Living Alone And This Is Not Related To Physical Dependence. Irina Chaves, Ana Rita Marques, Sofia Ramiro, Sofia Pedro, Kaleb Michaud, Frederick Wolfe, Elizabeth Benito-Garcia.
  1. Current Risk Factors for Rheumatoid Arthritis (RA) Work Disability: Recent Data from a US National Cohort. Saralynn H. Allaire, Frederick Wolfe, Jingbo Niu, Michael P. LaValley, Bin Zhang, Susan Reisine.
  1. Prevalence, Incidence and Predictors of Depression in Fibromyalgia. Robert S. Katz, Frederick Wolfe, Kaleb Michaud.
  1. Malignancies in the Abatacept RA Clinical Development Program: An Updated Epidemiological Assessment. A. Smitten, T. Simon, K. Qi, S. Suissa, J. Askling, J. Franklin, M. C. Hochberg, D. Lacaille, F. Wolfe.
  1. The Burden of Medical Expenses Does Not Fall Equally on All with RA: Increased Burden for the Poor and Disabled. Frederick Wolfe, Kaleb Michaud. National Data Bank for Rheumatic Diseases, Wichita, KS.
  1. Can Treatments or the Outcome of RA be Successful if the Patient Doesn't Think So? Patient Requirements for Successful Outcomes. Frederick Wolfe, Kaleb Michaud.
  1. Multicenter Validation of the Self-Reported Lupus Damage Index Questionnaire (LDIQ). Karen H. Costenbader, Munther Khamashta, Silvia Ruiz-Garcia, Maria Teresa Perez-Rodriguez, Michelle Petri, Jennifer Elliott, Elizabeth Karlson, Iris Navarro, John G. Hanly, Sasha Bernatsky, Timothy S. Shaver, Robert S. Katz, Eliza Chakravarty, Paul Fortin, Frederick Wolfe, Graciela Alarcon.
  1. Toward the Development of Revised Criteria for the Fibromyalgia Diagnosis. Frederick Wolfe, Daniel J. Clauw, Don L. Goldenberg, Robert S. Katz.

PUBLICATIONS: Articles, Books and LettersPUBLICATIONS: Articles, Books and Letters

  1. Wolfe F: SLE Latex Test Kit, JAMA, 226: 357, 1973.
  2. Wolfe F, Norris WL, Wilber M: ACR Standard Database Reconsidered, Arthritis Rheum 20:1556, 1977.
  3. Schumacher RH, Cockburn R, McCracken BE, Wenig P, Wolfe F: Essentials of a Differential Diagnosis of Rheumatoid Arthritis, Philadelphia, Smith Kline, 1981.
  4. Wolfe F: Fibrositis and Selection Bias. Arthritis Rheum 25: 1390, 1982.
  5. Wolfe F, Young DY: Rheumatoid Arthritis and Antecedent Tonsillectomy. J Rheumatol 10:309-321, 1983.
  6. Wolfe F, Cathey M, Kleinheksel S: Lenses and Neck Pain. JAMA 249:1707-1708, 1983.
  7. Wolfe F, Schurle DR, Lin JJ, Polland SM, Smith TW, Montgomery-Short R, James DL: Upper and Lower Airway Disease in Penicillamine Treated Patients with Rheumatoid Arthritis. J Rheumatol 10:406-410, 1983.
  8. Wolfe F, Cathey M: Prevalence of Primary and Secondary Fibrositis. J Rheumatol 10:965-968, 1983.
  9. Decker JL, McShane DJ, Esdaile JM, Hathaway DE, Levinson JE, Liang MH, Medsger Jr TA, Meenan RF, Mills JA, Roth SH, Wolfe F (ACR Glossary Committee): Dictionary of the Rheumatic Diseases. Volume I: Signs and Symptoms. New York, Contact Associates, 1982.
  10. Decker JL, Esdaile J, Hathaway DE, Levinson JE, Liang MH, McShane DJ, Medsger TA, Meenan RF, Mills JA, Sharp JT, Tan EM, Wolfe F (ACR Glossary Committee): American Rheumatism Association Nomenclature and Classification of Arthritis and Rheumatism (1983). Arthritis Rheum 26:8 1029-1032, 1983.
  11. Wolfe F: Tender Points, Trigger Points, and the Fibrositis Syndrome. Clin Rheum Prac 2:36-38, 1984.
  12. Stone G, Wolfe F: Collateral Ligament Calcification Complicating Amyloidosis Associated with Reiter's Syndrome. J Rheumatol 11:248-250, 1984.
  13. Wolfe F, Sheon RP: The Diagnosis of Fibrositis, Diagnosis, July 1984.
  14. Wolfe F: Arthritis and Musculoskeletal Pain. Nursing Clinics of North America 19:565-574, 1984.
  15. Wolfe F, Cathey MA, Kleinheksel SM, Amos SP, Hoffman RG, Young DY, Hawley DJ: Psychological Status in Primary Fibrositis and Fibrositis Associated with Rheumatoid Arthritis. J Rheumatol 11:500-506, 1984.
  16. Wolfe F, Cathey MA, Kleinheksel S: Fibrositis in Rheumatoid Arthritis. J Rheumatol 11:814-818, 1984.
  17. Wolfe F: Tender Point Count: Clinical Significance in Rheumatoid Disease, Arthritis Rheum 28:479, 1985.
  18. Wolfe F, Hawley DJ: Remission in Rheumatoid Arthritis J Rheumatol 12: 245-252, 1985.
  19. Wolfe F, Cathey MA: The Epidemiology of Tender Points: A prospective study of 1520 patients. J Rheumatol 12:6 1164-1168, 1985.
  20. Wolfe F, Hawley DJ, Cathey MA, Caro X, Russell IJ: Fibrositis: Symptom Frequency and Criteria for Diagnosis. J Rheumatol 12:6 1159-1163, 1985.
  21. Germain BF, Dillard CO, Levi L, Mullen BJ, Rahman MA, Rowe HJ, Wolfe F: A Placebo-Controlled Study of Diclofenac Sodium for the Treatment of Osteoarthritis of the Hip and Knee. Curr Ther Res 37:259-268, 1985.
  22. Decker JL, McShane DJ, Esdaile JM, Levinson JE, Liang MH, Medsger Jr TA, Meenan RF, Mills JA, Wolfe F (ACR Glossary Committee): Dictionary of Rheumatic Diseases Volume II New York, 1985.
  23. Wendt RG, Wolfe F, McQueen D, Murphy P, Solomon H, Householder M: Polyarticular Pigmented Villonodular Synovitis in Children: Evidence for a genetic contribution. J Rheumatol 13:5 921-926, 1986
  24. Fries JF, Sharp J, Bloch DA, McShane DJ, Bluhm G, Forrester D, Gofton P, Weissman C, Genant H, Richman S, Wolfe F, Spitz P: Assessment of Radiologic Progression in Rheumatoid Arthritis (RA) A Randomized Controlled Trial. Arthritis Rheum 29:1 1-9, 1986.
  25. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell D, Roth SH: A Multi-Center Study of Utilization and Costs in Rheumatoid Arthritis. Arthritis Rheum 29:488-493, 1986.
  26. Wolfe F, Kleinheksel SM, Spitz PW, Lubeck DP, Fries JF, Young DY, Mitchell D, Roth S: A Multi-Center Study of Hospitalization in Rheumatoid Arthritis: Frequency, Medical-Surgical Admissions, and Charges. Arthritis Rheum: 29:614-619, 1986.
  27. Wolfe F, Kleinheksel SM, Spitz PW, Lubeck DP, Fries JF, Young DY, Mitchell DM, Roth SH: A Multi-Center Study of Hospitalization in Rheumatoid Arthritis: Effect of Health Care System, Severity, and Regional Difference J Rheumatol:13:277-284. 1986.
  28. Fries JF, Spitz PW, Mitchell DM, Roth SH, Wolfe F, Bloch DA: Impact of specific therapy upon rheumatoid arthritis. Arthritis Rheum 19:620-627, 1986.
  29. Wolfe F, Schindler J, Cathey MA, Hawley D, Balser JP, Kennedy S: Clinical trials with R-IFN-G in rheumatoid arthritis.In:S.Pincus,ed. Biologically Based Immunomodulators in the Therapy of Rheumatic Diseases.Elisivier, 379-397, 1986.
  30. Wolfe F: The clinical syndrome of fibrositis. Am J Med: 81(3A):7-14, 1986.
  31. Wolfe F: The development of criteria for the diagnosis of fibrositis. Am J Med: 81(3A):99-104, 1986.
  32. Cathey MA, Kleinheksel S, Hawley D, Wolfe F: Socio -economic impact of fibrositis. Am J Med:81(3A):78-84, 1986.
  33. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Cooke TD, Christy W, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley S, McShane DJ, Mankin H, Medgser T, Meenan R, Mikkelsen W, Moskowitz R, Murphy W, Rothschild B, Segal M, Sokoloff L, Wolfe F: Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29: 1039-1049, 1986.
  34. Caro, XJ, Wolfe F, Johnston WH, Smith AL: A controlled and blinded study of immunoreactant deposition at the dermal-epidermal junction of patients with primary fibrositis syndrome. J Rheumatol 13:1086-1092, 1986.
  35. Pincus T, Callahan LF, Bradley LA, Vaughn WK, Wolfe F: Elevated Minnesota Multiphasic Personality Inventory (MMPI) hypochondriasis, depression and hysteria scores in patients with rheumatoid arthritis reflect disease rather than psychological problems. Arthritis Rheum 29: 1456-1467.1986.
  36. Wolfe F, Fries JF: ARAMIS today: moving toward internationally distributed data banks. Clin Rheum 6:93-102.1987.
  37. Altman R, Fries JF, Bloch DA, Carstens J, Cooke D, Genant H, Gofton P, Groth H, McShane DJ, Murphy WA, Sharp JT, Spitz P, Williams CA, Wolfe F: Radiographic Assessment of Progression in Osteoarthritis. Arthritis Rheum 30:1213-1225, 1987.
  38. Khan MA, Wolfe F, Kleinheksel SM, Molta C: HLA DR4 and B27 in familial and sporadic rheumatoid arthritis. Scan J of Rheum:16:433-436, 1987.
  39. Wolfe F, Kleinheksel SM, Khan MA: Prevalence of familial occurrence in patients with rheumatoid arthritis. Br J of Rheum 27(S2):150-152, 1988.
  40. Wolfe F: Fibrositis, Fibromyalgia and Musculoskeletal Disease: The Current Status of the Fibrositis Syndrome. Arch Phys Med and Rehabil 69:527-531, 1988.
  41. Hawley DJ, Wolfe F: Anxiety and depression in rheumatoid arthritis: A prospective study of 400 patients. J Rheumatol 15(6):932-941, 1988.
  42. Wolfe F, Kleinheksel S, Cathey MA, Hawley DJ, Spitz PW, Fries JF: The clinical value of the HAQ disability index in patients with rheumatoid arthritis. J Rheumatol 15:1480-1488, 1988.
  43. Wolfe F: Fibromyalgia in the elderly: differential diagnosis and treatment. Geriatrics 43:57-68, 1988.
  44. Wolfe F: Fibromyalgia: Whither Treatment (Editorial) J Rheumatol 15:1047-1049,1988.
  45. Wolfe F, Kleinheksel SM, Khan MA: Familial versus sporadic rheumatoid arthritis: A comparison of the demographic and clinical characteristics of 860 patients. J Rheumatol 15:400-404, 1988.
  46. Wolfe F: Age of death of parents of patients with rheumatoid arthritis: Data from a middle class sample. J Rheumatol 16:735-739,1989.
  47. Cathey MA, Wolfe F, Kleinheksel SM, Miller S, Pitetti KH:   Functional ability and work status in patients with fibromyalgia. Arthritis Care & Res 1(2):1-15, 1988.
  48. Hawley DJ, Wolfe F, Cathey MA: Pain, disability and psychological status: A 12 month study of severity in fibromyalgia. J Rheumatol 15:1551-1556, 1988.
  49. Khan MA, Yamashita TS, Reynolds TL, Wolfe F, Khan MK: HLA-DR4 genotype frequency and gender effect in familial rheumatoid arthritis. Tissue 15770/2166,1988.
  50. Gao X, Ball EJ, Dombrausky L, Olsen NJ, Pincus T, Khan MA, Wolfe F, Stastny P: Class II Human leukocyte antigens and T Cell Receptor Polymorphisms in Patients with Rheumatoid Arthritis. Am J Med 85:14-16, 1988.
  51. Decker JL, McShane DJ, Wolfe F, et al, (ACR Glossary Committee). Dictionary of Rheumatic Diseases. Volume III, New York, 1988.
  52. Wolfe F: Non-pharmacologic therapy: What works? (Editorial) Arthritis Care & Res 1:1-3, 1988.
  53. Wolfe F: Fibromyalgia: The clinical syndrome. Rheum Dis Clin North Amer 1989;15:1-19.
  54. Wolfe F: The design of a fibromyalgia criteria study. J Rheumatol 1989
  55. Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, Schindler JD: Double-blind trial of recombinant y-Interferon versus placebo in the treatment of rheumatoid arthritis.   Arthritis Rheum 1989; 32:964-973.
  56. Wolfe F: EMG-biofeedback in fibromyalgia syndrome-Reply. J Rheumatol 16(7): 1013-1014, 1989.
  57. Wolfe F: Methodologic and statistical problems in the epidemiology of fibromyalgia. In J.R. Friction, E.A. Ewad, eds.: Myofascial Pain and Fibromyalgia. Raven Press, 1990;147-163.
  58. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DM, Tugwell P, Abeles M, Campbell SM, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the multicenter criteria committee, Arthritis Rheum 1990;33:160-172.
  59. Callahan LF, Pincus, T, Wolfe F:A contrasting view on rheumatoid arthritis. (Letter) AJPH 79:1308.
  60. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, Anderson L, Block S, Irby R, Wolfe F, Gall E, Torretti D, Biundo J, Small R, Coblyn J, Polisson R: Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. Arthritis Rheum 1990;33:330-338.
  61. Cannon GW, Emkey RD, Denes A, Cohen SA, Saway P, Wolfe F, Jaffer AM, Weaver AL, Cogen L, Gulinello, Kennedy SM, Schindler JD: Prospective Two Year Follow?up of recombinant interferon?gamma in rheumatoid arthritis. J Rheumatol 1990;17:304-310.
  62. Wolfe F:The epidemiology of fibromyalgia.Rheum Dis Clin North Am 1990; 16:681-698.
  63. Krantz SB,   Sawada KI, Wolfe F, Bocagno J: Erythropoietin: Receptors and clinical use in rheumatoid arthritis. Int J Cell Cloning 1990; 8 Suppl 1:181-95; discus.
  64. Wolfe F: 50 years of anti?rheumatic therapy: The prognosis of rheumatoid arthritis. J Rheumatol 17 (suppl)1990;12: Supp 22:24-32.
  65. Pincus T, Olsen NJ, Russell IJ, et al.: Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89:161-168.
  66. Wolfe F, Hawley DJ, and Cathey MA: Termination of slow acting anti?rheumatic therapy in rheumatoid arthritis: A 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
  67. Wolfe F, Cathey MA: Assessment of functional ability in patients with fibromyalgia (Letter): Arch Int Med: 1990; 150:460.
  68. Wolfe F: Two Muscle Pain Syndromes: fibromyalgia and the myofascial pain syndrome. Pain Management 1990;3 153-164.
  69. Wolfe F: The Fibromyalgia Syndrome. Arthritis and Rheumatism Primary Care Review 1990; 2: No.4, 1-8.
  70. Wolfe F: Diagnosis of Fibromyalgia: the new criteria. J Musculo Med 1990; 7, 53-69.
  71. Altman R, Alarcon GS, Appelrouth D, et al.: The American College of Rheumatology Criteria for the Classification and Reporting of Osteoarthritis of the Hand. Arthritis Rheum 1990; 33:1601-1610.
  72. Wolfe F: Sleep Disturbance in Fibromyalgia (Reply). 1990;Arthritis.Rheum.
  73. Wolfe F: The prognosis of rheumatoid arthritis. In Bellamy N, ed: Prognosis in the rheumatic diseases; Klewer Academic Publishers, Dordrecht, 1991; 37-82.
  74. Wolfe F: Fibromyalgia. In Bellamy N, ed: Prognosis in the rheumatic diseases. Klewer Academic Publishers, Dordrecht, 1991; 321-332.
  75. Hawley DJ, Wolfe F, Cathey MA, and Roberts FK:Marital Status and Demographic Characteristics of Clinic Patients with Rheumatoid Arthritis, Fibromyalgia, and Other Rheumatic Disorders:A Study of 7,293 patients. J Rheumatol 1991;18: 654-660.
  76. Wolfe F, and Cathey MA: Analysis of Methotrexate Treatment Effect In A Longtudinal Observational Study: Utility of Cluster Analysis J Rheumatol 1991; 18:672-677.
  77. Sharp JT, Wolfe F, Mitchell DM, and Bloch D.: The progression of erosions and joint space narrowing scores in rheumatoid arthritis during the first 25 years of disease. Arthritis Rheum 1991; 34: 660-668.
  78. Wolfe F: Gout and Hyeruricemia. Am. Family Practitioner 1991; 43: 2141-2150.
  79. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke T.D., Daniel W, Feldman D, Greenwald R, Hochberg M, Howell D, Ike R, Kapila P, Kaplan D, Koopman W, Marino C, McDonald E, McShane D.J.,Medsger T, Michel B, Murphy W.A., Osial T, Ramsey-Goldman R, Rothschild B, Wolfe F: The American College of Rheumatology Criteria for the Classification and Reporting of Osteoarthritis of the Hip. Arthritis Rheum 1991; 34, 505-514.
  80. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, Anderson L, Block S, Small R, Wolfe F, Gall E, Torretti D, Polisson R: Methotrexate in rheumatoid arthritis: Effects on disease activity in a multicenter prospective study. J Rheumatol 1991;18:3, 334-338.
  81. Wolfe F and Pincus T: Standard self?report questionnaires in routine clinical and research practice - An opportunity for patients and rheumatologists. J Rheumatol 1991;18: 643-646.
  82. Hawley DJ and Wolfe F: Are the results of controlled clinical trials and observational studies in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: An analysis of 122 studies. J.Rheumatol 1991;18:1008-1014.
  83. Wolfe F and Cathey MA: The Effect of Age on Methotrexate Efficacy and Toxicity. J.Rheumatol 1991; 18:973-977.
  84. Wolfe F and Cathey MA:The Misdiagnosis of Gout and Hyperuricemia. J Rheumatol 1991;18:1232-1234.
  85. Wolfe F: The epidemiology of NSAID associated Gastrointestinal Disease. Eur J Rheum Inflamm 1991;11:12-28.
  86. Wolfe F: Criteria for Fibromyalgia: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. In Muller, W. (Editor), Generalisierte Tendomyopathie (Fibromyalgie). Steinkopf Verlag Darmstadt, 1991;13-22.
  87. Wolfe F, Hawley DJ, Cathey MA: Health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J.Rheumatol 1991; 18:1290-1297.
  88. Wolfe F, Cathey MA, and Roberts FK:The latex test revisited: Rheumatoid factor testing in 8,287 rheumatic disease patients: Arthritis Rheum 1991;34:951-960.
  89. Wolfe F and Cathey MA:The Assessment and Prediction of Functional Disability in Rheumatoid Arthritis.   J Rheumatol 1991; 18:1298-1306.
  90. Hawley DJ and Wolfe F: Pain, Disability, and Pain/Disability Relationships in Seven Rheumatic Disorders: A study of 1,522 Patients. J Rheumatol 1991;18:1522-1557.
  91. Pincus T and Wolfe F: Treatment of Rheumatoid Arthritis: Challenges to Traditional Paradigms (Editorial). Ann Int Med 1991;115:825-227.
  92. Hawley DJ, Wolfe F, and Cathey MA: The Sense of Coherence Questionnaire in Patients with Rheumatic Disorders   J Rheumatol 1992; 19:1912-1918.
  93. Wolfe F: Fibromyalgia and cervical pain: Diagnosis and rehabilitative treatment of neuromusculoskeletal injuries.In Tollison CD, Satterthwaite JR, eds.: Painful Cervical Trauma: Diagnosis And Rehabilitative Treatment Of Neuromusculoskeletal Injuries, Williams & Willkins, Baltimore, 1992, 319-336.
  94. Wolfe F: Inflammatory rheumatic disorders involving the cervical spine. In Tollison CD,Satterthwaite JR, eds. In Painful Cervical Trauma: Diagnosis And Rehabilitative Treatment Of Neuromusculoskeletal Injuries, Williams & Wilkins, Baltimore 1992, 348-361.
  95. Hawley DJ and Wolfe F: Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other health status measures in Rheumatoid Arthritis: Results of short term clinical trials and observational studies versus long term observational studies. Arthritis Care Res 1992;5:130-136.
  96. Wolfe F, Simons DG, Fricton JR, et alThe Fibromyalgia and Myofascial Pain Syndromes - A Preliminary Study of Tender Points and Trigger Points in Persons with Fibromyalgia, Myofascial Pain Syndrome and No Disease.   J Rheumatol 1992; 19:944-951.
  97. Pincus T and Wolfe F: Gold Therapy for Rheumatoid Arthritis - Response.   Ann Intern Med 1992; 117:170
  98. Wolfe, F:. The Use of Classification Criteria in the Diagnosis of Rheumatoid Arthritis - Comment.   Arthritis Rheum 1992; 35:844.
  99. Wolfe F: Gout and Uric Acid Excretion - Reply.   Amer Fam Physician 1992; 45:50
  100. Hochberg MC, Chang R, Dwosh I, Lindsey S, Pincus T, Wolfe F: The 1991 American College of Rheumatology revised criteria for the classification of global functional status in rheumatoid arthritis.   Arthritis Rheum 1992; 35:498-502.
  101. Felson D, Anderson J, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams J, Wolfe F: American College of Rheumatology Core Set of Disease Activity Measures for Use in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36:729-740.
  102. Parker JC, Bradley LA, DeVellis RM, Gerber LH, Holman HR, Keefe FJ, Lawrence TS, Liang MH Lorig KR, Nicassio PM, Revenson TA, Rogers MP, Wallston KA, Wilson MG, Wolfe F: Biopsychosocial contributions to the management of arthritis disability: Proceedings from an NIDRR-sponsored conference. Arthritis Rheum 1993; 52:332-337.
  103. Wolfe F: Disability and the Dimensions of Distress in Fibromyalgia. J Musculo Pain 1993; 1:65-88.
  104. Bennett, RM, Smythe, HA, and Wolfe, F: Recognizing Fibromyalgia. Patient Care 26:211-228, 1992.
  105. Wolfe F: The curious case of intramuscular gold. Rheum Dis Clin   North Am 1993, 19:173-188.
  106. Wolfe F: Hugh A Smythe.   J Musc Pain 1993; 1:13-16.
  107. Wolfe F, Hawley DJ, Cathey M.A.: Measurement of gold treatment effect in clinical practice: Evidence for the efficacy of intramuscular gold therapy. J Rheumatol   1993; 20:797-802.
  108. Hawley DJ, Wolfe F.: Depression is not more common in rheumatoid arthritis: a ten year longitudinial study of 6,608 patients. J Rheumatol 1993; 20:2025-2031.
  109. Wolfe F: Fibromyalgia and related disorders. In Advances in Neurology. (In Press 1992).
  110. Wolfe F: On Diagnosis and Certainty. J Musc Pain 1993; 1:17-36.
  111. Wolfe F: The Epidemiology of fibromyalgia.   J Musculo Med 1993; 1:137-148.
  112. Wolfe F: Clinical, laboratory, and radiographic assessments. Curr Opinion in Rheum 1993; 5:138-145.
  113. Cannon GW, Emkey RD, Denes A, et al: Prospective 5-year follow-up of recombinant interferon-g in rheumatoid arthritis. J Rheumatol 1993; 20:1867-1873.
  114. Wolfe F and Hawley DJ. Fibromyalgia. In: Kelley WN, Harris EDJ, Ruddy S, Sledge CB, eds. Textbook of Rheumatology (Supplement). 1993:
  115. Parker, JC, Bradley LA, DeVellis RN, Gerber LH, Holman HR, Keefe FJ, Lawrence TS, Liang MH, Lorig KR, Nicassio PM, Revenson TA, Rogers MP, Wallston KA, Wilson MG, Wolfe F:   Biopsychosocial contributions to the management of arthritis disability: Blueprints from an NIDRR-sponsored conference. Arthritis Rheum 1993; 36:885-889.
  116. Michel BA, Bloch DA, Wolfe F, Fries J: Fractures in Rheumatoid Arthritis - An Evaluation of Associated Risk Factors. J Rheumatol 1993, 20:1666-1669.
  117. Wolfe F. Fibromyalgia and Myofascial Pain Syndrome. In: Portnoy R, ed. 1993:
  118. Wolfe F. Fibromyalgia and problems in classification of musculoskeletal disorders. In: Vaeroy H and Merskey H, eds. Progress in fibromyalgia and myofascial pain. Amsterdam:Elsevier Science Publishers B.V., 1993:217-235.
  119. Wolfe F and Hawley DJ: The relationship between clinical activity and depression on rheumatoid arthritis.   J Rheumatol 1993; 20:2032-2037.
  120. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA: The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome clinic: A study of 1141 patients.   J Rheumatol 1993; 20:2005-2009.
  121. Strand   V, Lipsky P, Cannon G, Calabrese L, Wiesenhutter C, Cohen S, Olsen N, Lee M, Lorenz T, Nelson B, Cush J, Wolfe F, Fleischmann R, Karr R, Krick G, Medsger T, Rigby W, Fox D,Swartz T, Multz C, Weisman M: CD5 Plus RA Investigators Group: "Effects of administration of an anti-CD5 immunoconjugate in rheumatoid arthritis: Results of two Phase II studies.   Arthritis Rheum   1993; 36:620-630.
  122. Sharp J, Wolfe F, Corbett M, Isomaki H, Mitchell D, Furst D, Sibley J, Shipley M: Radiological progression in rheumatoid arthritis -How many patients are required in a treatment trial to test disease modification? Ann Rheum Dis 1993, 52:332-337.
  123. Wolfe F: When to diagnosis fibromyalgia.   Rheum Dis Clin North Am, 1994; 20: 485-501.
  124. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481-494.
  125. Wolfe F, Cathey MA, Hawley DJ: A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand. J. Rheum 1994; 23: 255-259.
  126. Hawley DJ, Wolfe F: Effect of light and season on pain and depression in subjects with rheumatic disorders. Pain 1994; 59:227-234.
  127. Wolfe F, Ross K, Anderson J, Russell IJ: Aspects of fibromyalgia on the general population: sex, pain threshold and fibromyalgia symptoms. J. Rheumatol 1995; 22:151-156.
  128. Wolfe F, Hawley DJ, Ross K, Anderson J: The increase in depression rates and scores in clinic patients with rheumatoid arthritis, osteoarthritis, and fibromyalgia compared to persons in the general population. 1994 (UnPub).
  129. Wolfe F: Rheumatoid and Osteoarthritis: epidemiologic data. APS Bulletin 1994; 4:(2) 15.
  130. Wolfe F, Hawley DJ: Fibromyalgia in the adult Danish Population (Letter). Scand J Rheumatol 1994; 23:55.
  131. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
  132. Wolfe F: Post-traumatic fibromyalgia: a case report narrated by the patient. Arthritis Care Res; 7:161-165,1994.
  133. Wolfe F: On criteria and classification. J.Mus.Pain 1994; 2:21-37.
  134. Wolfe F: Interrater reliability of the tender point criterion for fibromyalgia (Letter). J Rheumatol 1994; 21:370.
  135. Wolfe F: Data collection and utilization: a methodology for clinical practice and clinical research. In: Wolfe F and Pincus T, eds.: Prognosis and Treatment of Rheumatoid Arthritis. New York: Marcel Dekker, 1994:463-514.
  136. Wolfe F, Michaud K: The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994; 21:1227-1237.
  137. Felson D, Anderson J, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams J, Wolfe F: Reduced joint counts in rheumatoid arthritis clinical trials. Arthritis Rheum 1994; 37:463-464.
  138. Wolfe F: Aspects of the epidemiology of fibromyalgia. J.Musc.Pain 1994;2:65-74.
  139. Wolfe F, Pincus T, Callahan LF: Introduction. Rheumatoid Arthritis: Pathogenesis, Assessment Outcome and Treatment. New York: Marcel Dekker, 1994; -74.
  140. Wolfe F, Weinblatt ME, Kaplan H, Germain BF, et al.: Methotrexate in rheumatoid arthritis - A five-year prospective multicenter study. Arthritis Rheum 1994; 37:1492-1498.
  141. Wolfe, F: Fibromyalgia: in Anesthesia: biologic foundations, Edited by Biebuyck J, Lynch C, Maze M, Saidman LJ, Yaksh TL and Zapol W. Lippincott-Raven 1997, 905-920.
  142. Wolfe F and Pincus T: Data Collection in the clinic. Rheumatic Disease Clinics of North America 1995;21:321-358.
  143. Wolfe F and Pincus T: Health Status Questionnaires. Rheumatic Disease Clinics of North America. 1995;21:445-464.
  144. Wolfe F and Pincus T: A Data Base for Rheumatoid Arthritis. Rheumatic Disease Clinics of North America. 1995;21:481-500.
  145. Wolfe F: Fibromyalgia. In: Sessle BJ, Bryant PS, Dionne RA, eds. Temporomandibular Disorders and Related Pain Conditions. Seattle: IASP Press, 1995:31-46.
  146. Peloso, P, Wolfe F, Hawley DJ: Back Pain in Rheumatoid Arthritis. Submitted.
  147. Wolfe F; Hawley DJ; Peloso PM; Wilson K; Anderson J, P: Back pain in osteoarthritis of the knee. Arthritis Care Res 1996 Oct;9(5):376-83
  148. Wolfe F, Wilson K, Anderson J, Hawley DJ: The prevalence and meaning of fatigue in rheumatic disease. J. Rheumatol. 1996; 23:1407-1417.
  149. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain threshold and fibromyalgia symptoms in the general population. J. Rheumatol 24: 555-559, 1997.
  150. Wolfe F, Aarflot T, Bruusgaard D, Henriksson KG, Littlejohn G, Moldofsky, H, Raspe HH, Vaeroy H: Fibromyalgia and Disability. Report of the Moss working group on medical-legal aspects of chronic widespread pain complaints and fibromyalgia. Scand J Rheumatol 1995; 24: 112-8.
  151. Wolfe F and the Vancouver Fibromyalgia Consensus Group. The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J. Rheumatology 1996; 23: 534-539.
  152. Wolfe F: The epidemiology of drug treatment failure in rheumatoid arthritis. Bailliares Clinical Rheumatology 1995;9: 619-632
  153. Mata S, Wolfe F, Lawrence J, Esdaile F. Absence of an association of RA and DISH: a case control study. J. Rheumatol. 1995.
  154. Wolfe F, Potter JW. Fibromyalgia and work disability: is fibromyalgia a disabling disorder? Rheum Dis Clin N Amer. 1996;22:369-92.
  155. Altman, RD, Hochberg M, Murphy Jr., WA, Wolfe F and Lequesne M.: Atlas of individual radiographic features in osteoarthritis. Osteoarthritis and Cartilage 1995; 3: 3-70.
  156. Fibromyalgia and Myofascial Pain Syndrome. In Pain management: theory and practice. Edited Portenoy, RK and Kanner, RM. Chapter 7, pp 145-169, 1996, F.A. Davis Co, Philadelphia, PA.
  157. Plesh O, Wolfe F, Lane NE. The Prevalence of Fibromyalgia and Temporomandibular Disorders (TMD) in Patients. J Rheumatol. 23: 1948-1952, 1996
  158. Williams CA, Bloch DA, Sibley J, et al. Lymphoma and leukemia in rheumatoid arthritis: are they associated with azathioprine, cyclophosphamide, or methotrexate? A matched case-control study in the Arthritis, Rheumatism and Aging Medical Information System (ARAMIS) population. J Clin Rheumatol. 1996;2:64-72.
  159. Wolfe F, Anderson J, Harkness D, et al. The Work and Disability Status of Persons With Fibromyalgia. 1997;25:1171-1178.
  160. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol. 1996;23:13-22.
  161. Felson DT, Anderson JJ, Boers M, et al. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
  162. McDermott M, Kastner DL, Holloman JD, et al. The role of T cell receptor beta chain genes in susceptibility to rheumatoid arthritis. Arthritis Rheum. 1995;38:91-5.
  163. F. Wolfe. The comparative usefulness of the C-reactive protein and the erythrocyte sedimentation rate in patients with rheumatoid arthritis. J.Rheumatol, 1997;24:1477-1485
  164. F. Wolfe and D.J. Hawley. Measurement of the quality of life in rheumatic disorders using the EuroQol. Brit.J.Rheumatology, 1997;36:786-793.
  165. F. Wolfe. PWCORRS - An enhanced correlation display for Stata. Stata Technical Bulletin STB-35: 22-24, 1997.
  166. F. Wolfe. A comparison of rheumatoid factor by nephelometry and latex methods: clinical and laboratory significance. Arthritis Care and Research1998;11:89-93.
  167. F.Wolfe. The crp but not the esr is associated with clinical severity in patients osteoarthritis of the knee or hip. J. Rheumatol. 1997;24:1486-1488.
  168. F. Wolfe. Adverse drug reactions of DMARDS and DC-ARTS in Rheumatoid Arthritis. Clin.Exp.Rheumatol. 1997:15:S75-S81.
  169. F.Wolfe. The fibromyalgia problem [Editorial]. J.Rheumatol. 1997;24:1247-1249
  170. F.Wolfe. What use are fibromyalgia control points? J.Rheumatol. 1998;25:546-550.
  171. F.Wolfe. The relationship between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann. Rheum. Dis. 1997;56:269-271.
  172. Frederick Wolfe, Janice Anderson, Deborah Harkness, Robert M. Bennett, Xavier Caro, Don M. Goldenberg, I. Jon Russell, and Muhammad B. Yunus. Health Status and Disease Severity in Fibromyalgia: Results of a Six Center Longitudinal Study. Arthritis.Rheumatism 1997;1560-1570.
  173. Frederick Wolfe, Janice Anderson, Deborah Harkness, Robert M. Bennett, Xavier Caro, Don M. Goldenberg, I. Jon Russell, and Muhammad B. Yunus. A Prospective, Longitudinal, Multicenter Study of Service Utilization and Costs in Fibromyalgia. Arthritis.Rheumatism 1997;1571-1579.
  174. D. Buskila, L. Neumann, G. Vaisberg, D. Alkalay, F. Wolfe. Increased rates of fibromyalgia following cervical spine trauma: a controlled study of 161 cases of traumatic injury. Arthritis.Rheumatism 40:446-452,1997
  175. Wolfe, F. The Prognosis of Rheumatoid Arthritis: Assessment of Disease Activity and Disease Severity in the Clinic. Am.J.Med (Suppl), 103:12S-18S.
  176. Hawley DJ, Wolfe F. Fatigue and musculoskeletal pain. Phys Med Rehab Clin N A.: 8:101-11, 1997.
  177. Wolfe, F. and Zwillich, SH. The long-term outcomes of rheumatoid arthritis: A 23 year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis.Rheum. 1998; 41: 1072-1082.
  178. Wolfe, F. and Hawley. The long-term outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J Rheumatol   1998;25(11):2108-17.
  179. Wolfe, F. and Sharp. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum.   1998;41(6):1072-82.
  180. Pincus, JT and Wolfe,F.: Patient Self-report questionnaires as integral to clinical care. The Behavioral Measurements Letter 5:3-7, 1997.
  181. Pincus, T. and Wolfe, F.: “No evidence of disease” in rheumatoid arthritis using methotrexate in combination with other drugs: a contemporary goal for rheumatology care? Clin. Exp. Rheum 1997; 15 591-596.
  182. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG et al.   Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum.   1998;41(5):778-99.
  183. Wolfe F, Albert DA, and Pincus T. A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis. Arthrit.Care Res.   1998;11(5):375-81.
  184. Wolfe F. Fibromyalgia in a grand bio-psycho-social model - Reply. J Rheumatol   1998;25(5):1029-30.
  185. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology 38: 355-361,1999.
  186. Wolfe F. and Anderson J. Silicone breast implants and the risk of fibromyalgia and rheumatoid arthritis J.Rheumatol. 26: 2025-2028 1999.
  187. Wolfe F. “Silicone Related Symptoms” Are Common In Patients with Fibromyalgia: No Evidence for A New Disease. J.Rheumatol 26: 1172-1175 1999.
  188. Wolfe F. and Hawley DJ. Psychosocial factors and the fibromyalgia syndrome. Zeitschrift fur Rheumatologie (Supp 2) 57: 88-91, 1999.
  189. Wolfe F. and Hawley DJ. Evidence of Disordered Symptom Appraisal in Fibromyalgia: Increased Rates of Reported Comorbidity and Comorbidity Severity. Clin.Exp.Rheumatol. 17:297-303, 1999.
  190. Wolfe F. and Pincus T. Listening to the Patient: A practical Guide to Self-report Questionnaires In Clinical Care. Arthritis Rheum. 42:1798-1808 1999.
  191. Wolfe F. Critical issues in longitudinal and observational studies including study purpose, short term versus long term studies, selection of study instruments, methods of carrying out studies, outcomes to be studied. J.Rheumatol 26:469-472, 1999.
  192. Wolfe F. What use are fibromyalgia control points? Dr. Wolfe replies. J Rheumatol   1998;25(12):2476.
  193. Wolfe F and Winfield JB. Fibromyalgia Consensus Report: A few more comments. J Clin.Rheumatol   1998;4(3):118-9..
  194. F. Wolfe, M. Lassere, D. van der Heijde, G. Stucki, M. Suarez-Almazor, T. Pincus, K. Eberhardt, T.K. Kvien, D. Symmons, A. Silman, P. van Riel, P. Tugwell and M. Boers. Preliminary Core Set of Domains and Reporting Requirements for Longitudinal Observational Studies in Rheumatology. J.Rheumatol 26:484-489, 1999
  195. Ehrich E, Levy, R, Zeng, Q, Seidenberg, B., Schnitzler, T, Wolfe F, Morrison B, Gertz B, Mcilwain H, Weisman M, Bolognese J: Effect of specific Cox-2 inhibition in osteoarthritis of the knee: a 6-week double blind, placebo-controlled, pilot study of rofecoxib. J. Rheum. 26:2438-2447, 1999.
  196. Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C: Substantial superiority of semi-flexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semi-flexed (MTP) and schuss views. J.Rheumatol. 26:2664-2674, 1999 .
  197. Wolfe F and Skevington S: The Epidemiology of Distress. 2000, J. Rheumatol. 27:2000-2009, 2000.
  198. Wolfe F: Psychological distress and rheumatic disease (Editorial). Scand. J. Rheumatol. 28:131-136, 1999.
  199. Wolfe, F. The effect of smoking on clinical, laboratory and radiographic status in RA. J.Rheumatol. 27:630-639, 2000.
  200. Wolfe, F. Kong, SX: Rasch analysis of the Western Ontario MacMaster Questionnaire (WOMAC) in 2205 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Ann.Rheum.Dis 1999: 563-568.
  201. Aronoff GM, Markowitz M, Dorto AJ, Ranavaya MI, Talmage JB, Wolfe F, Andersson G, Cocchiarella L, Harlason III R, Neville Jr CH, et al.   AADEP Position Paper - Fibromyalgia: impairment and disability issues.   American Academy of Disability Examing Physicians   1999;8(3 - Special Pull out section):1-10.
  202. Wolfe F, Zhao S and Lane N. Preference for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) over Acetaminophen by Rheumatic Disease Patients: A Survey Of 1799 Patients with Osteoarthritis, Rheumatoid Arthritis and Fibromyalgia. Arthritis.Rheum 2000; 43:378-385.
  203. Pincus T, Swearingen C and Wolfe F. Toward a multi-dimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis.Rheum 1999; 42:2220-2230.
  204. Wolfe F, Kong SX, Watson, DJ: Gastrointestinal Symptoms and Health-Related Quality of Life in Patients with Arthritis. J.Rheumatol. 2000; 27:1373,1378.
  205. Maini,R.N.; Wolfe,F.: Workshop summary: health outcomes and health economic issues surrounding the use of biological therapies in patients with rheumatoid arthritis. Rheumatology 38: 58-49, 1999.
  206. Smolen,J.S.; Strand,V; Cardiel,M.; Edworthy,S.; Furst,D.; Gladman,D.; Gordon,C.; Isenberg,D.A.; Klippel,J.H.; Petri,M.; Simon,L.; Tugwell,P.; Wolfe,F. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains. J.Rheumatol. 26:504-507, 1999.
  207. Wolfe F, Hawley J, Goldenberg DL, Russell IJ, Buskila D, Neuman L. The Assessment of Functional Impairment in Fibromyalgia: Rasch Analyses of 5 Functional Scales – FIQ, HAQ, MHAQ, IHAQ, SF-36 – and the Development of a New Scale, the FHAQ. J.Rheumatol. 27: 1989-1999, 2000.
  208. Wolfe F, van der Heijde DM, Larsen A. Assessing Radiographic Status of Rheumatoid Arthritis: Introduction of a Shortened Erosion Scale (SES). J Rheumatol. 2000: 27:2090-2099. Press).
  209. Wolfe F, Hawley DJ. The Comparative Risk and Predictors of Adverse GI Events in Rheumatoid Arthritis and Osteoarthritis: A Prospective, 13-Year Study of 2,131 Patients. J Rheumatol. 2000; 27:1668-1674.
  210. Wolfe F. The Importance Of GI Symptom Severity In Rheumatoid And Osteoarthritis: Symptom Rates And Risk For Gastrointestinal Hospitalization. J Rheumatol. 2000: 1661-1667.
  211. The Level of Inflammation in Rheumatoid Arthritis Is Determined Early and Remains Stable Over the Longterm Course of the Illness. J Rheumatol 2001;28:1817-24.
  212. Management of Fibromyalgia [Letter] Ann.Int.Med 2000, 132: 1004.
  213. Hawley DJ, Wolfe F, Lue FA, Moldofsky H.   Seasonal Symptoms and Seasonal Severity in Patients with Rheumatic diseases: A study of 1,424 patients with up to 24 years symptom follow-up. J Rheumatol 2001;28:1900-9.
  214. J. M. Berthelot, M. Klarlund, D. McGonagle, H. J. Bernelot-Moens, A. Calin, B. Harrison, H. R. Schumacher, K. Kaarela, A. A. Drosos, J. L. Hulsemann, W. H. Koh, Y. T. Konttinen, L. Punzi, K. Tanimoto, H. J. Williams, F. Wolfe, C. A. Zerbini, and A. Saraux. Lessons from an international survey of paper cases of 10 real patients from an early arthritis clinic. CRI (Club Rhumatismes et Inflammation) Group. J Rheumatol 28 (5):975-981, 2001.
  215. T. Pincus, T. Sokka, and F. Wolfe. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 44 (6):1234-1236, 2001.
  216. F. Wolfe. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 28 (5):982-989, 2001.
  217. F. Wolfe, J. J. Cush, J. R. O'Dell, A. Kavanaugh, J. M. Kremer, N. E. Lane, L. W. Moreland, H. E. Paulus, T. Pincus, A. S. Russell, and K. R. Wilskie. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 28 (6):1423-1430,   2001.
  218. F. Wolfe, J. R. O'Dell, A. Kavanaugh, K. Wilske, and T. Pincus. Evaluating severity and status in rheumatoid arthritis. J Rheumatol 28 (6):1453-1462, 2001.
  219. F. Wolfe and V. Strand. Radiography of rheumatoid arthritis in the time of increasing drug effectiveness.    Curr.Rheumatol Reports 3(1):46-52, 2001.
  220. T. Pincus, G. G. Koch, T. Sokka, J. Lefkowith, F. Wolfe, J. M. Jordan, G. Luta, L. F. Callahan, X. Wang, T. Schwartz, S. B. Abramson, J. R. Caldwell, R. A. Harrell, J. M. Kremer, R. L. Lautzenheiser, J. A. Markenson, T. J. Schnitzer, A. Weaver, P. Cummins, A. Wilson, S. Morant, and J. Fort. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 44 (7):1587-1598, 2001
  221. F. Wolfe, T. Pincus, and J. F. Fries. Usefulness of the HAQ in the clinic. Ann Rheum Dis   2001; 60: 811.
  222. D. A. Albert, S. Aksentijevich, S. Hurst, J. F. Fries, and F. Wolfe. Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models.   J Rheumatol 27(3):644-652, 2000.
  223. T. Pincus and F. Wolfe. An infrastructure of patient questionnaires at each rheumatology visit: Improving efficiency and documenting care. J.Rheumatol. 27(12): 2727-2730, 2000.
  224. F. Wolfe and H.K. Choi, Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement. Ann Rheum Dis 2001;60:994–996.
  225. F. Wolfe. Wolfe F. The psychometrics of functional status questionnaires: room for improvement.   J Rheumatol 2002; 29(5):865-868.
  226. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002; 3(3):170-176.
  227. J Duryea, S. Zaim, F Wolfe. Neural network based automated algorithm to identify joint locations on hand/wrist radiographs for arthritis assessments. Med.Phys. 29 (3), March 2002, 403-411.
  228. H. K. Choi, M. A. Hernan, J. D. Seeger, and F. Wolfe. Methotrexate therapy and mortality with rheumatoid arthritis. Lancet   359: 1173-1177, 2002.
  229. Wolfe F. The determination and measurement of functional disability in rheumatoid arthritis. Arthritis Res 2002; 4 Suppl 2:S11-S15
  230. Choi HK, Michaud K, Wolfe F. Utility measures in rheumatic diseases. Arthritis Rheum (suppl) 2002; 46(9).
  231. Ethgen O, Kahler KH, Kong SX, Reginster JY, Wolfe F. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol 2002; 29(6):1147-1155.
  232. Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002; 46(9):2320-2329.
  233. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002; 41(12):1346-1356.  
  234. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29(3):467-473.
  235. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29(5):1015-1022.
  236. Wolfe F, Lane NE. The longterm outcome of osteoarthritis: rates and predictors of joint space narrowing in symptomatic patients with knee osteoarthritis. J Rheumatol 2002; 29(1):139-146.
  237. Wolfe F. Pain Extent and Diagnosis: Development and Validation of the Regional Pain Scale (RPS) in 12,799 Rheumatic Disease Patients. J Rheumatol 2003; 30: 369-378.
  238. Wolfe F, Pincus T, Thompson A, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Rheum. 2003; 49: 59-63.
  239. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30(1):36-40.
  240. Wolfe, F. The Use of Self-Report Questionnaires in the Clinical Care of Patients With Rheumatoid Arthritis. Chapter, Textbook of Rheumatology. In Press 2003.
  241. F. Wolfe, K. Michaud, O. Gefeller, and H. K. Choi. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum. 48 (6):1530-1542, 2003.
  242. Wolfe, F: Stop Using the American College of Rheumatology Criteria in the Clinic (Editorial) J Rheumatol 2003;30:1671-1672.
  243. Wolfe F, Michaud K, Stephenson B, Doyle J. Toward a definition and method of assessment of treatment failure: the case of leflunomide versus methotrexate. J Rheumatol 2003;30:1725–32.
  244. Michaud K, Messer J, Choi HK, Wolfe F. Direct Medical Costs and Their Predictors in Persons with Rheumatoid Arthritis: a 3-Year Study of 7,527 Patients. Arthritis Rheum 2000; 48: 2750-2763.
  245. Michaud K, Wolfe F. Congestive Heart Failure in Rheumatoid Arthritis: Rates, Predictors and the Effect of Anti-TNF Therapy. Am J Med.; 2004 (in press).
  246. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis Infection in Patients with Rheumatoid Arthritis and the Effect of Infliximab Therapy. Arthritis Rheum. 2004; 2: 372–379.
  247. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol. 2004 Apr;31(4):695-700.
  248. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, Fort J. Patient preference for Placebo, Acetaminophen or Celecoxib Efficacy Studies (PACES): Two randomized placebo-controlled cross-over clinical trials in patients with osteoarthritis of the knee or hip. Ann Rheum Dis. 2004 Apr 13.
  249. Wolfe F. A short history of data banking in the United States from 1974 to 2003. J Rheumatol Suppl. 2004 Mar;69:41-5.
  250. Wolfe F, Michaud K, Burke TA, Zhao SZ. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol. 2004 Feb;31(2):355-8.
  251. Wolfe F. From the outside of Plato's cave. Rheumatology (Oxford). 2004 Jan;43(1):112-3.
  252. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology (Oxford). 2004 Jan;43(1):4-6 (editorial).
  253. Wolfe F, Fries JF. Rate of death due to leukemia/lymphoma in patients with rheumatoid arthritis. Arthritis Rheum. 2003 Sep;48(9):2694-5 (letter).
  254. Sharp JT, Wolfe F, Lassere M, Boers M, Van Der Heijde D, Larsen A, Paulus H, Rau R And Strand V. Variability of Precision in Scoring Radiographic Abnormalities in Rheumatoid Arthritis by Experienced Readers. J Rheumatol 2004;31:1062-72.
  255. Wolfe F, Zhao S, Reynolds M, and Pettitt D. Blood Pressure Destabilization and Edema Among 8538 Users of Celecoxib, Rofecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs (NSAID) and Nonusers of NSAID Receiving Ordinary Clinical Care. J Rheumatol 2004;31:1143-51.
  256. Z. Fewell, M. A. Hernan, F. Wolfe, H. Tilling, H. K. Choi, and A. C. Sterne. Controlling for time-dependent confounding using marginal structural models. Stata Journal 4 (4):402-420, 2004.
  257. S. A. Mazzuca, K. D. Brandt, B. P. Katz, K. A. Lane, J. D. Bradley, L. W. Heck, S. T. Hugenberg, S. Manzi, L. W. Moreland, C. V. Oddis, T. J. Schnitzer, L. Sharma, F. Wolfe, and D. E. Yocum. Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. Arthritis Rheum. 51 (6):933-940, 2004.
  258. R. L. Robinson, H. G. Birnbaum, M. A. Morley, T. Sisitsky, P. E. Greenberg, and F. Wolfe. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J.Rheumatol. 31 (8):1621-1629, 2004.
  259. R. Stern and F. Wolfe. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J.Rheumatol. 31 (8):1538-1545, 2004.
  260. F. Wolfe, K. Michaud, and T. Pincus. HAQ-II: Development and Validation of a Revised Version of the Health Assessment Questionnaire (HAQ). Arthritis Rheum. 50:3296-3305, 2004.
  261. F. Wolfe, L. Caplan, and K. Michaud. Measuring the efficacy and effectiveness of rheumatoid arthritis therapy: time to change our thinking and adopt a new model. J.Rheumatol. 31 (12):2317-2319, 2004.
  262. F. Wolfe, K. Michaud, K. Kahler, and M. Omar. The Short Arthritis Assessment Scale: a brief assessment questionnaire for rapid evaluation of arthritis severity in research and clinical practice. J.Rheumatol. 31 (12):2472-2479, 2004.
  263. F. Wolfe. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J.Rheumatol. 31 (10):1896-1902, 2004.
  264. F. Wolfe and K. Michaud. Data collection, maintenance, and analysis for rheumatic disease research. Rheum.Dis.Clin.North Am. 30 (4):753-768, 2004.
  265. F. Wolfe and K. Michaud. Data collection, maintenance, and analysis for rheumatic disease research. Rheum.Dis.Clin.North Am. 30 (4):753-768, 2004.
  266. T. Pincus, V. Strand, G. Koch, I. Amara, B. Crawford, F. Wolfe, S. Cohen, and D. Felson. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum. 48 (3):625-630, 2003.
  267. Allaire S, Wolfe F, Niu J, LaValley M, Michaud K. Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum 2005; 53(4):603-8.
  268. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32(6):1013-9.
  269. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005; 52(7):2015-25.
  270. Caplan L, Russell AS, Wolfe F. Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol 2005; 32(10):1863-5.
  271. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32(11):2130-5.
  272. Lee AT, Li W, Liew A, Bombardier C, Weisman M, Massarotti EM et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun 2005; 6(2):129-33.
  273. Mazzuca SA, Brandt KD, Schauwecker DS, Katz BP, Meyer JM, Lane KA et al. Severity of joint pain and kellgren-lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis. J Rheumatol 2005; 32(8):1540-6.
  274. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol 2005; 32(4):575-7.
  275. Pincus T, Yazici Y, Yazici H, Kavanaugh AF, Kremer JM, Wolfe F. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: Comment on the article by Smolen et al. Arthritis Rheum 2005; 52(12):4044-5.
  276. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW et al. Replication of Putative Candidate-Gene Associations with Rheumatoid Arthritis in >4,000 Samples from North America and Sweden: Association of Susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005; 77(6):1044-60.
  277. Walker N, Michaud K, Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 2005; 32(6):1006-12.
  278. Ward RJ, Chris Buckland-Wright J, Wolfe F. Relationships between tibial rim alignment and joint space width measurement reproducibility in non-fluoroscopic radiographs of osteoarthritic knees. Osteoarthritis Cartilage 2005.
  279. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32(10):2016-24.
  280. Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford) 2005; 44 Suppl 4:iv18-iv22.
  281. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005; 32(4):583-9.
  282. Wolfe F, Michaud K, Pincus T. A Composite Disease Activity Scale for Clinical Practice, Observational Studies and Clinical Trials: The Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005; 32(12):2410-5.
  283. Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol 2005; 32(7):1261-6.
  284. Wolfe F, van der Heijde D, Larsen A. Assessing radiographic status of rheumatoid arthritis: introduction of a shortened erosion scale. In: Bezruczko N, editor. Rasch measurement in health sciences. Chicago: JAM Press; 2005.
  285. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005; 52(12):3873-9.
  286. Wolfe F, Michaud K. A brief introduction to the National Data Bank for Rheumatic Diseases. Clin Exp Rheumatol 2005; 23(5):S168-S171.
  287. Wolfe F, Michaud K, Pincus T, Pangan AL, Kent j. Usefulness Of A Visual Analog Function Scale In Ra Clinical Trials: Increased Sensitivity Compared With Conventional Measures. Arthritis.Rheum. 50. 2005.
  288. Wolfe F. Why the HAQ-II can be an effective substitute for the HAQ. Clin Exp Rheumatol 2005; 23(5 Suppl 39):S29-S30.
  289. Wolfe F, Katz RS, Michaud K. Jaw Pain: Its Prevalence and Meaning in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia. J Rheumatol 2005; 32(12):2421-8.
  290. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005; 32(10):1875-83.
  291. Allaire S, Wolfe F, Niu J, LaValley M. Contemporary Prevalence and Incidence of Work Disability Associated with Rheumatoid Arthritis. 2006.
  292. Allaire S, Wolfe F, Niu J, Baker N, Michaud K, LaValley M. Extent of occupational hand use among persons with rheumatoid arthritis. Arthritis Rheum 2006; 55(2):294-9.
  293. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354(8):795-808.
  294. Dewitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 2006; 166(1):57-63.
  295. Finckh A, de PP, Katz JN, Neumann G, Lu Y, Wolfe F et al. Performance of an automated computer-based scoring method to assess joint space narrowing in rheumatoid arthritis: a longitudinal study. Arthritis Rheum 2006; 54(5):1444-50.
  296. Finckh A, Choi HK, Wolfe F. Progression of radiographic joint damage in different eras. Trends towards milder disease in Rheumatoid Arthritis are attributable to improved therapy. Ann Rheum Dis 2006.
  297. Garcia EB, Michaud K, Wolfe F. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists. J Rheumatol 2006; 33(4):779-84.
  298. Goligher EC, Duryea J, Liang MH, Wolfe F, Finckh A. Radiographic joint space width in the fingers of patients with rheumatoid arthritis of less than one year's duration. Arthritis Rheum 2006; 54(5):1440-3.
  299. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: A comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum 2006; 54(1):169-76.
  300. Michaud K, Wolfe F. The association of rheumatoid arthritis and its treatment with sinus disease. J Rheumatol 2006; 33(12):2412-5.
  301. Wolfe F, Michaud K, Strand V. Dr. Wolfe, et al reply. J Rheumatol 2006; 33(2):435.
  302. Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol 2006; 33(10):1942-51.
  303. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45(11):1370-5.
  304. Wolfe F, Rasker JJ. The symptom intensity (SI) scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol. In press 2006.
  305. F. Wolfe, J. J. Rasker, M. Boers, G. A. Wells, and K. Michaud. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 57 (6):935-942, 2007.
  306. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54(2):628-34.
  307. L. Caplan, F. Wolfe, A. S. Russell, and K. Michaud. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 34 (4):696-705, 2007.
  308. Wolfe F, Michaud K. Effect of Methotrexate and Anti TNF Therapy on Lymphoma Risk in Rheumatoid Arthritis in 19,562 Patients during 89,710 Person-years of observation. Arthritis Rheum. In press 2007.
  309. F. Wolfe and K. Michaud. Assessment of Pain in Rheumatoid Arthritis: Minimal Clinically Significant Difference, Predictors, and the Effect of Anti-Tumor Necrosis Factor Therapy. J Rheumatol, 2007.
  310. E. Benito-Garcia, K. Michaud, and F. Wolfe. The Effect of Low-Dose Aspirin on the Decreased Risk of Development of Dyspepsia and Gastrointestinal Ulcers Associated to Cyclooxygenase-2 Selective Inhibitors. J Rheumatol, 2007.
  311. P. H. Dessein, G. R. Norton, A. J. Woodiwiss, B. I. Joffe, and F. Wolfe. Influence of Nonclassical Cardiovascular Risk Factors on the Accuracy of Predicting Subclinical Atherosclerosis in Rheumatoid Arthritis. J Rheumatol 34 (5):943-951, 2007.
  312. H. S. Lee, P. Irigoyen, M. Kern, A. Lee, F. Batliwalla, H. Khalili, F. Wolfe, R. F. Lum, E. Massarotti, M. Weisman, C. Bombardier, E. W. Karlson, L. A. Criswell, R. Vlietinck, and P. K. Gregersen. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 56 (6):1745-1753, 2007.
  313. C. A. Marra, S. A. Marion, D. P. Guh, M. Najafzadeh, F. Wolfe, J. M. Esdaile, A. E. Clarke, M. A. Gignac, and A. H. Anis. Not all "quality-adjusted life years" are equal. J Clin.Epidemiol. 60 (6):616-624, 2007.
  314. F. Wolfe, L. Caplan, and K. Michaud. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 36 (3):172-178, 2007.
  315. F. Wolfe. The effective use of questionnaires in clinical practice. Arthritis Rheum 57 (5):705-706, 2007.
  316. F. Wolfe and K. Michaud. Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices. Arthritis Rheum 56 (7):2135-2142, 2007.
  317. F. Wolfe and K. Michaud. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 56 (9):2886-2895, 2007.
  318. K. Michaud and F. Wolfe. Comorbidities in rheumatoid arthritis. Best.Pract.Res.Clin.Rheumatol 21 (5):885-906, 2007.
  319. Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: The jury is still out. Arthritis Rheum 2008; 59(8):1082-9.
  320. Allaire S, Wolfe F, Niu J, LaValley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 2008; 59(4):474-80.
  321. Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 2008; 58(2 Suppl):S79-S88.
  322. Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ. Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin 2008.
  323. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum 2008; 58(1):26-35.
  324. Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study. Arthritis Rheum 2008; 59(8):1090-6.
  325. Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Mikuls TR et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008; 35(6):1015-22.
  326. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 2008; 47(4):535-41.
  327. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O et al. Cost-Effectiveness of Abatacept in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Tumor Necrosis Factor-alpha Antagonists. J Rheumatol 2008.
  328. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008; 58(4):939-46.
  329. Wolfe F, Michaud K. Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. J Rheumatol 2008; 35(6):1023-30.
  330. Wolfe F, Michaud K. The challenges of determining RA disease activity and remission in clinical practice. Nat Clin Pract Rheumatol 2008.
  331. Benito-Garcia E, Michaud K, Wolfe F. The Effect of Low-Dose Aspirin on the Decreased Risk of Development of Dyspepsia and Gastrointestinal Ulcers Associated to Cyclooxygenase-2 Selective Inhibitors. J Rheumatol 2007.
  332. Wolfe F, Rasker JJ. Fibromyalgia. In: Firestein GS, Budd RC, Harris Jr ED, McInnes IB, Ruddy S, Sergent JS, editors. Kelley's Textbook of Rheumatology. 8th ed: Elsevier; 2008.
  333. Wolfe F, Petri M, Alarcon GS, Goldman J, Chakravarty EF, Katz RS, et al. Fibromyalgia, Systemic Lupus Erythematosus (SLE), and Evaluation of SLE Activity. J Rheumatol 2008
  334. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. Arthritis Rheum 2008;58(9):2612-21.
  335. Wolfe F, Petri M, Alarcon GS, Goldman J, Chakravarty EF, Katz RS, et al. Fibromyalgia, Systemic Lupus Erythematosus (SLE), and Evaluation of SLE Activity. J Rheumatol 2009.
  336. Costenbader KH, Khamashta M, Ruiz-Garcia S, Perez-Rodriguez MT, Petri M, Elliott J, et al. Development and Initial Multi-center Validation of the Self-Assessed Lupus Damage Index Questionnaire. Submitted 2009.
  337. Pons-Estel B, Sanchez-Guerrero J, Romero-Diaz J, Inglesias A, Bonfa E, Shinjo SK, et al. Validation of the Spanish, Portuguese and French Versions of the Lupus Damage Index Questionnaire: Data from North and South America, Spain and Portugal. Submitted 2009.
  338. Wolfe F, Alarcon GS, Costenbader KH, Karlson E, Katz RS, Michaud K. The Lupus Damage Index Questionnaire (LDIQ): Characteristics and Correlates in a Longitudinal Cohort. Submitted 2009.
  339. Allaire S, Wolfe F, Niu J, LaValley MP, Zhang B, Reisine S. Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort. Arthritis Rheum. 2009 Mar 15;61(3):321-8.
  340. Wolfe F. Fibromyalgianess. Arthritis Rheum. 2009 Jun 15;61(6):715-6.
  341. Wolfe F. Fibromyalgia wars. J Rheumatol. 2009 Apr;36(4):671-8.
  342. Wolfe F, Boers M, Felson D, Michaud K, Wells GA. Remission in rheumatoid arthritis: physician and patient perspectives. J Rheumatol. 2009 May;36(5):930-3.
  343. Wolfe F, Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum. 2009 May 15;61(5):667-73.
  344. Wolfe F, Michaud K. Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. J Rheumatol. 2009 Apr;36(4):831-6.
  345. Wolfe F, Michaud K. Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure. J Rheumatol. 2009 Jan;36(1):27-33.
  346. Wolfe F, Petri M, Alarcon GS, Goldman J, Chakravarty EF, Katz RS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol. 2009 Jan;36(1):82-8.